Liquid polymer compositions and systems for prolonged delivery of peptides as active pharmaceutical ingredients

Liquid drug compositions, which combine low molecular weight PEG-initiated liquid block copolymers with biocompatible solvents and divalent cations, solve the problems of high viscosity, high irritation and drug instability in existing liquid polymer delivery systems, and achieve stable sustained release and long-term delivery of peptide drugs.

CN114746080BInactive Publication Date: 2024-11-22TOLMAR INT LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080082220.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-09-30
Filing Date
2020-09-28
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing liquid polymer delivery systems suffer from problems such as high viscosity, the need for large needles, local irritation, and drug instability during long-term drug delivery, especially for peptide drugs that are prone to acid degradation, making it difficult to maintain chemical and physical stability.

Method used

A stable liquid drug composition is formed by using a low molecular weight PEG-initiated biodegradable liquid block copolymer, combined with a biocompatible solvent and divalent cations, avoiding reverse thermal gelation, ensuring that it remains in a liquid state in vivo and providing a sustained-release effect.

Benefits of technology

This technology enables stable and sustained release of peptide drugs in vivo, avoids local irritation, reduces injection force requirements, improves drug stability and compliance, and is suitable for long-term drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114746080B_ABST
    Figure CN114746080B_ABST
Patent Text Reader

Abstract

Liquid polymer pharmaceutical compositions having a biodegradable liquid polymer, a biocompatible solvent or a combination or mixture of solvents and / or cosolvents and an active pharmaceutical agent including a peptide can be used to provide an extended long-term sustained release of the drug to a subject and / or improve the stability of the active pharmaceutical agent. In various embodiments, the polymer can be initiated with a low molecular weight polyethylene glycol and / or can be a block copolymer comprising a low molecular weight polyethylene glycol block. In various further embodiments, the liquid polymer pharmaceutical composition can include a divalent cation, which can be provided in the form of a metal salt.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application is in the field of biodegradable liquid polymer compositions which can be administered into the body using a syringe or needle and which can be used to deliver drugs such as peptides into the body over an extended period of time. Background Art

[0002] Biodegradable polymers are well known for their use in biomedical applications such as sutures, surgical clips, staples, implants, and drug delivery systems. Such polymers include polyglycolides, polylactides, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanones, polyacetals, polyesteramides, polyamides, polyurethanes, polycarbonates, poly(amino acids), polyphosphazenes, polyketals, polyphosphates, polyhydroxybutyrates, polyhydroxyvalerates, and polyalkylene oxalates.

[0003] Initially, biodegradable polymers were solid materials that were used to form solid articles such as sutures, staples, surgical clips, tissue scaffolds, implants, or microcapsules and microparticles. Since the polymers are solid, all of their applications in the biomedical field require that the polymer structure be formed outside the body and then inserted into the body for use.

[0004] U.S. Pat. No. 5,278,201 to Dunn et al. ("the '201 patent") overcomes the administration problem of solid implants by dissolving a biodegradable solid polymer in a biocompatible solvent and injecting the solution into the body using a standard syringe and needle, wherein the polymer in the solution precipitates or coagulates upon contact with aqueous body fluids to form a solid implant matrix. The delivery system described in the '201 patent provides many advantages, including ease of manufacturing the polymer solution, introduction of the drug into the polymer solution just prior to administration, resulting in improved drug and polymer stability and no loss of drug during the manufacturing process, and the ability to terminally sterilize the polymer solution as well as the drug. However, this in situ forming polymer system still has several disadvantages. Because the polymer used is a solid with a relatively high molecular weight, the polymer solution formed by the combination of the solid polymer and the biocompatible solvent is quite viscous. Due to the high viscosity, a large inner diameter 18-21 gauge needle is required for administration and a considerable injection force is required. Furthermore, the viscous solutions are not easily injected into muscle tissue and solid implants formed from these polymer solutions often result in local irritation of the muscle tissue. For this reason, the aforementioned polymer solutions are usually injected subcutaneously, wherein the material forms a fairly clear and noticeable mass.

[0005] Dunn's U.S. Pat. No. 8,187,640 ("the '640 patent") addresses the problems associated with the solid implants of the '201 patent. The '640 patent discloses a composition of a biodegradable liquid polymer in combination with a biocompatible solvent that dissipates when the liquid polymer / solvent composition is placed in the body, thereby forming a viscous liquid polymer material in the form of a film, coating, plug, or other mass. The viscous liquid polymer material does not solidify when injected into the body, but instead remains in situ in a viscous liquid form and, when combined with a drug, provides both an initial burst release and a sustained release (extended release) of the drug.

[0006] PCT Publication No. WO2017024027 describes the manufacture of a low viscosity liquid polymer delivery system as disclosed in the '640 patent to determine the rate and duration of release of a drug after subcutaneous administration of the drug-loaded delivery system. It was determined that the delivery system of the '640 patent was not suitable for long-term extended delivery of a drug for more than, for example, 14 days. PCT Publication No. WO2017024027 discloses a liquid polymer composition different from that described in the '640 patent, which provides significantly improved sustained release of the drug compared to the '640 patent. The liquid polymer composition described in PCT Publication No. WO2017024027 includes a biodegradable liquid polymer having at least one carboxylic acid terminal group and a ratio of monomer units to carboxylic acid terminal groups between about 5:1 and about 90:1.

[0007] For the development of polymeric drug delivery carriers such as peptide drugs whose active ingredients are prone to acid degradation, it is a significant challenge to maintain the chemical and physical stability of active pharmaceutical ingredients throughout the life cycle of the drug product. For example, during the hydrolytic degradation of polymer implants in vivo, the pH of the polymer implant surrounding environment is reduced, which can lead to peptide instability. Previous studies have also shown that, depending on the primary sequence and high-level structure of the peptide, peptide (class) drugs are prone to degradation in the presence of polymers containing lactide and / or glycolide. Therefore, there is a need in the art for polymeric drug delivery compositions and systems including peptide drugs, wherein the peptide drugs remain stable to provide suitable sustained release for target applications. Summary of the invention

[0008] One aspect of the present invention is to provide a pharmaceutical composition comprising: an active pharmaceutical ingredient comprising a peptide or a pharmaceutically acceptable ester or salt thereof, wherein the peptide comprises at least one accessible amine group; and a biodegradable liquid block copolymer comprising a copolymer block comprising: (1) monomer residues selected from D,L-lactide, D-lactide, L-lactide, and glycolide, and combinations thereof, and (2) monomer residues selected from ε-caprolactone, trimethylene carbonate, and combinations thereof; and a polymer block comprising a low molecular weight polyethylene glycol (PEG); wherein the biodegradable liquid block copolymer is synthesized by initiation with the low molecular weight PEG; and wherein the viscosity of the biodegradable liquid block copolymer does not spontaneously increase with increasing temperature.

[0009] In various embodiments, the biodegradable liquid block copolymer is not a reverse thermogel.

[0010] In various embodiments, the end groups of the biodegradable liquid block copolymer are not covalently modified.

[0011] In various embodiments, the biodegradable block copolymer may be a triblock copolymer according to the formula: ABA, wherein A is the copolymer block of (i), and B is a polymer block comprising PEG.

[0012] In various embodiments, the biodegradable block copolymer may be a diblock copolymer according to the formula: AB or BA, wherein A is the copolymer block of (i) and B is a polymer block comprising PEG, and the PEG is methoxy-PEG.

[0013] In various embodiments, the copolymer blocks of (i) may have a molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomer residues of between about 10:90 and about 90:10.

[0014] In various embodiments, the copolymer blocks of (i) may have a molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomer residues of between about 20:80 and about 80:20.

[0015] In various embodiments, the copolymer blocks of (i) may have a molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomer residues of between about 25:75 and about 75:25.

[0016] In various embodiments, the copolymer blocks of (i) may have a molar ratio of lactide monomer residues to caprolactone and / or trimethylene carbonate monomer residues of 75:25.

[0017] In various embodiments, the molar ratio of ethylene glycol residues in the low molecular weight PEG to all other monomer residues in the biodegradable copolymer may be between about 10:90 and 50:50.

[0018] In various embodiments, the molar ratio of ethylene glycol residues in the low molecular weight PEG to all other monomer residues in the biodegradable copolymer can be at least about 10:90.

[0019] In various embodiments, the molar ratio of ethylene glycol residues in the low molecular weight PEG to all other monomer residues in the biodegradable copolymer can be at least about 20:80.

[0020] In various embodiments, the molar ratio of ethylene glycol residues in the low molecular weight PEG to all other monomer residues in the biodegradable copolymer can be at least about 30:70.

[0021] In various embodiments, the molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomers to ethylene glycol residues in the biodegradable copolymer may be X:Y:Z, wherein X may be any number between about 25 and about 75, Y may be any number between about 5 and about 45, and Z may be any number between about 5 and about 55, such that the sum of X, Y, and Z is 100.

[0022] In various embodiments, the polyethylene glycol may have a number average molecular weight of 200-2000 Daltons.

[0023] In various embodiments, the low molecular weight polyethylene glycol may have a number average molecular weight of less than or about 900 Daltons.

[0024] In various embodiments, the low molecular weight polyethylene glycol may have a number average molecular weight of less than or about 600 Daltons.

[0025] In various embodiments, the low molecular weight polyethylene glycol may have a number average molecular weight of less than or about 400 Daltons.

[0026] In various embodiments, the low molecular weight polyethylene glycol has a number average molecular weight of less than or about 300 Daltons.

[0027] In various embodiments, the pharmaceutical composition may further include a biocompatible solvent.

[0028] In various embodiments, the pharmaceutical composition may further include a divalent cation.

[0029] In various embodiments, the divalent cation may be selected from magnesium, calcium, and zinc.

[0030] In various embodiments, the divalent cation may be provided as a metal salt. The metal salt may, but need not, be selected from magnesium acetate, magnesium chloride, calcium chloride, zinc acetate, and zinc chloride.

[0031] In various embodiments, the metal salt can be magnesium acetate, and the magnesium acetate can be at a concentration between about 0.01 mg / mL and about 2.75 mg / mL of the pharmaceutical composition.

[0032] In various embodiments, the metal salt can be magnesium chloride, and the magnesium chloride can be at a concentration between about 0.01 mg / mL and about 3.75 mg / mL of the pharmaceutical composition.

[0033] In various embodiments, the metal salt can be calcium chloride, and the calcium chloride can be at a concentration between about 0.01 mg / mL and about 1.6 mg / mL of the pharmaceutical composition.

[0034] In various embodiments, the metal salt can be zinc acetate, and the zinc acetate can be at a concentration between about 0.01 mg / mL and about 8.2 mg / mL of the pharmaceutical composition.

[0035] In various embodiments, the metal salt can be zinc chloride, and the zinc chloride can be at a concentration between about 0.01 mg / mL and about 1.4 mg / mL of the pharmaceutical composition.

[0036] In various embodiments, the peptide may include at least two basic amino acids selected from the group consisting of arginine, histidine, lysine, and combinations thereof.

[0037] Another aspect of the present invention is to provide a pharmaceutical composition comprising: an active pharmaceutical ingredient comprising a linear peptide or a pharmaceutically acceptable ester or salt thereof, wherein the linear peptide does not have an accessible amine group; a biocompatible solvent; a biodegradable copolymer comprising lactide residues and monomer residues selected from caprolactone, trimethylene carbonate, and combinations thereof, wherein the biodegradable copolymer comprises at least one carboxylic acid terminal group; and a divalent cation.

[0038] In various embodiments, the divalent cation may be selected from magnesium and zinc.

[0039] In various embodiments, the divalent cation may be provided as a metal salt. The metal salt may, but need not, be selected from magnesium acetate, zinc chloride, and zinc acetate.

[0040] In various embodiments, the metal salt can be magnesium acetate, and the magnesium acetate can be at a concentration between about 0.01 mg / mL and about 1.65 mg / mL of the pharmaceutical composition.

[0041] In various embodiments, the metal salt can be zinc chloride, and the zinc chloride can be at a concentration between about 0.01 mg / mL and about 1.1 mg / mL of the pharmaceutical composition.

[0042] In various embodiments, the metal salt can be zinc acetate, and the zinc acetate can be at a concentration between about 0.01 mg / mL of the pharmaceutical composition and about 7.15 mg / mL of the pharmaceutical composition.

[0043] In various embodiments, the biodegradable copolymer can be synthesized using a hydroxy acid initiator. The hydroxy acid initiator can, but need not, be glycolic acid.

[0044] Another aspect of the present invention is to provide a pharmaceutical composition comprising: an active pharmaceutical ingredient comprising a cyclic peptide or a pharmaceutically acceptable ester or salt thereof, wherein the cyclic peptide has no accessible amine group or has one accessible amine group; a biocompatible solvent; a biodegradable copolymer comprising lactide residues and monomer residues selected from caprolactone, trimethylene carbonate, and combinations thereof, wherein the biodegradable copolymer comprises at least one carboxylic acid terminal group; and a divalent cation.

[0045] In various embodiments, the divalent cation may be zinc.

[0046] In various embodiments, the divalent cation may be provided as a metal salt. The metal salt may, but need not, be selected from zinc chloride and zinc acetate.

[0047] In various embodiments, the metal salt can be zinc chloride, and the zinc chloride can be at a concentration between about 0.01 mg / mL and about 1.2 mg / mL of the pharmaceutical composition.

[0048] In various embodiments, the metal salt can be zinc acetate, and the zinc acetate can be at a concentration between about 0.01 mg / mL and about 7.3 mg / mL of the pharmaceutical composition.

[0049] In various embodiments, the biodegradable copolymer can be formed using a hydroxy acid initiator. The hydroxy acid initiator can, but need not, be glycolic acid.

[0050] In various embodiments, the biodegradable copolymer may have a weight average molecular weight between about 1 kDa and about 35 kDa.

[0051] In various embodiments, the biocompatible solvent may include at least one selected from the following: N-methyl-2-pyrrolidone (NMP), acetone, butyrolactone, ε-caprolactone, N-cyclohexyl-2-pyrrolidone, diethylene glycol monomethyl ether, dimethylacetamide, dimethylformamide, dimethyl sulfoxide (DMSO), ethyl acetate, ethyl lactate, N-ethyl-2-pyrrolidone, glycerol formal, ethoxylated tetrahydrofurfuryl alcohol (glycofurol, glycogen), N-hydroxyethyl-2-pyrrolidone, isopropylidene glycerol (acetone glycerol, isopropylidene glycerol), lactic acid, methoxypolyethylene glycol, methoxypropylene glycol, methyl acetate, methyl ethyl ketone, methyl lactate, low molecular weight (MW) polyethylene glycol (PEG), polysorbate 80, polysorbate 60, polysorbate 40, polysorbate 20, polyoxyl 35 hydrogenated castor oil, polyoxyl 40 hydrogenated castor oil, sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, benzyl alcohol, n-propanol, isopropanol, t-butyl alcohol, propylene glycol, 2-pyrrolidone, alpha-tocopherol, triacetin, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, triethyl citrate, esters thereof, and combinations and mixtures thereof.

[0052] In various embodiments, the biocompatible solvent can include N-methyl-2-pyrrolidone (NMP).

[0053] In various embodiments, the composition can have a viscosity suitable for injection at room temperature.

[0054] In various embodiments, after administering the pharmaceutical composition to an animal, the biocompatible solvent can dissipate within the animal's body and the biodegradable copolymer can form a biodegradable, non-solid implant in situ within the animal's body.

[0055] Another aspect of the invention is the use of a pharmaceutical composition as described herein as a medicament or for the treatment of a disease.

[0056] Another aspect of the present invention is to provide a method of treating a subject with an active pharmaceutical ingredient comprising administering to the subject a pharmaceutical composition as described herein.

[0057] Another aspect of the present invention is to provide a delivery system for administration of a pharmaceutical composition, comprising a syringe; and a pharmaceutical composition as described herein, wherein the composition is contained within the syringe.

[0058] In various embodiments, the syringe can be a mixing syringe.

[0059] In various embodiments, the injector may be an autoinjector. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 The percent recovery of abaloparatide acetate (AA) as a function of time (days) at 25°C is shown for LPT formulations including the following lactide:caprolactone copolymers initiated with different polymer initiators: acid-initiated polymers wherein the lactide to caprolactone molar ratio is about 25:75 (◆, AAX1); acid-initiated polymers wherein the lactide to caprolactone molar ratio is about 75:25 (■, AAX2); PEG-300-initiated polymers wherein the lactide to caprolactone molar ratio is about 75:25 (▲, AAX3); and dodecanol-initiated polymers wherein the lactide to caprolactone molar ratio is about 75:25 (●, AAX4).

[0061] Figure 2A and 2B Shown is an HPLC chromatogram of an LPT formulation comprising an acid-triggered LPT polymer and abaparatide acetate (AA). Figure 2A is the chromatogram of a fresh sample (day 0) of the formulation and Figure 2B Chromatogram for samples stored at 25°C for 2 days.

[0062] Figure 3 Shown is the percent recovery of abaparatide acetate (AA) as a function of time (days) at 37°C for LPT formulations including PEG-300 initiated lactide:caprolactone (75:25) copolymers in the presence of the following divalent cation salts: magnesium chloride (□, AA1), calcium chloride (■, AA2), zinc chloride (●, AA3), and a control formulation without salt (▲, AAX8).

[0063] Figure 4 Shown is the percent recovery of abaloparatide acetate (AA) as a function of time (days) at 37°C for LPT formulations including PEG-300 initiated lactide:caprolactone copolymers in the presence of the following magnesium salts: 1.1 mg / mL ("low" concentration) magnesium acetate (○, AA4), 2.2 mg / mL ("high" concentration) magnesium acetate (◇, AA5), 1.25 mg / mL "low" concentration magnesium chloride (x, AA6), 2.5 mg / mL "high" concentration magnesium chloride (□, AA7), and a control formulation containing no salt (▲, AAX9).

[0064] Figure 5Shown is the percent recovery of abaloparatide acetate (AA) as a function of time (days) at 37°C for LPT formulations including PEG-300 initiated lactide:caprolactone copolymer (75:25), the presence of magnesium acetate as follows: 0.55 mg / mL ("low" concentration) magnesium acetate (○, AA8), 1.1 mg / mL ("high" concentration) magnesium acetate (◇, AA9), and a control formulation containing no salt (▲, AAX10).

[0065] Figure 6 Shown for LPT formulations including PEG-300 initiated lactide:caprolactone copolymer (75:25) in the presence of the following zinc salts: 2.5 mg / mL ("low" concentration) zinc acetate ( Figure 2. Percent recovery of abaloparatide acetate (AA, AA10), 5.68 mg / mL (“high” concentration) zinc acetate (+, AA11), 1.0 mg / mL zinc chloride (◆, AA12), and a control formulation without salt (▲, AAX11) at 37°C as a function of time (days).

[0066] Figure 7 Shown is the percent recovery of released leuprolide acetate (LA) as a function of time (days) at 37°C for LPT formulations including lactide:caprolactone copolymers (75:25) initiated with different polymer initiators: acid initiated polymer (■, LAX1), PEG-300 initiated polymer (▲, LAX2), and dodecanol initiated polymer (●, LAX3).

[0067] Figure 8 Shown is the percent recovery of leuprolide acetate (LA) as a function of time (days) at 37°C for LPT formulations comprising an acid-initiated lactide:caprolactone copolymer (75:25), the presence of magnesium acetate as follows: 0.53 mg / mL ("low" concentration) magnesium acetate (○, LA1), 1.08 mg / mL ("high" concentration) magnesium acetate (◇, LA2), and a control formulation containing no salt (■, LAX4).

[0068] Fig. 9 Shown for LPT formulations including acid initiated lactide:caprolactone copolymer (75:25) with the following zinc salts present: 2.14 mg / mL ("low" concentration) zinc acetate ( LA3), 5.0 mg / mL ("high" concentration) zinc acetate (+, LA4), 0.15 mg / mL ("low" concentration) zinc chloride (●, LA5), 0.93 mg / mL ("high" concentration) zinc chloride (◆, LA6), and a control formulation without salt (■, LAX4), the percent recovery of leuprolide acetate (LA) as a function of time (days) at 37°C.

[0069] Fig.10 Shown is the percent recovery of lanreotid acetate (LNA) as a function of time (days) at 37°C for LPT formulations including lactide:caprolactone copolymers (75:25) initiated with different polymer initiators: acid-initiated polymers (■, LNAX1), dodecanol-initiated polymers (●, LNAX2), and PEG-300-initiated polymers (▲, LNAX3).

[0070] Fig.11 Shown is the percent recovery of lanreotide acetate (LNA) as a function of time (days) at 37°C for LPT formulations comprising an acid-initiated lactide:caprolactone copolymer (75:25), the presence of magnesium acetate as follows: 0.55 mg / mL ("low" concentration) magnesium acetate (●, LNA1), 1.1 mg / mL ("high" concentration) magnesium acetate (◆, LNA2), and a control formulation containing no salt (■, LNAX4).

[0071] Fig.12 Shown for LPT formulations including acid initiated lactide:caprolactone copolymer (75:25) in the presence of the following zinc salts: 2.3 mg / mL ("low" concentration) zinc acetate ( LNA3), 5.0 mg / mL ("high" concentration) zinc acetate (+, LNA4), 0.2 mg / mL ("low" concentration) zinc chloride (●, LNA5), 1.0 mg / mL ("high" concentration) zinc chloride (◆, LNA6), and a control formulation without salt (■, LNAX4), percent recovery of lanreotide acetate (LNA) as a function of time (days) at 37°C.

[0072] Fig.13 Shown is the percent recovery of octreotide acetate (OA) as a function of time (days) at 37°C for LPT formulations including lactide:caprolactone copolymers (75:25) initiated with different polymer initiators: acid initiated polymer (■, OAX1), dodecanol initiated polymer (●, OAX3), and PEG-300 initiated polymer (▲, OAX4).

[0073] Fig.14Shown is the percent recovery of octreotide acetate (OA) as a function of time (days) at 37°C for LPT formulations comprising an acid-initiated lactide:caprolactone copolymer (75:25), the presence of magnesium acetate at 0.55 mg / mL ("low" concentration) (○, OA1), 1.1 mg / mL ("high" concentration) (◇, OA2), and a control formulation containing no salt (■, OAX2). DETAILED DESCRIPTION

[0074] The present invention generally relates to sustained-release pharmaceutical formulations including biodegradable liquid polymers. Certain active pharmaceutical ingredients (APIs), such as peptide drugs, are susceptible to chemical or physical degradation, including, but not limited to acid degradation and acylation, in the presence of polymers containing lactide and / or glycolide (e.g., poly(lactide-co-glycolide) (PLG) polymers) used in pharmaceutical compositions of the prior art. The effect of poly(lactide-co-glycolide) (PLG) copolymers on the stability of peptide molecules can be affected by many factors, such as monomer ratio, molecular weight, polydispersity index (PDI), polymer end groups, drug solubility, solvent properties, and the concentration of polymers in solution. Therefore, maintaining stability throughout the life cycle of polymer-based sustained-release products can be a major challenge for drug molecules that are susceptible to acid degradation, such as peptide drugs. For example, during the hydrolytic degradation of polymer implants, pH will drop in the local environment, and this can lead to peptide instability, which can be further exacerbated at higher temperatures, such as body temperature. Therefore, it can be particularly difficult to formulate pharmaceutically acceptable compositions that allow sustained release of drugs for these types of APIs.

[0075] The present invention provides pharmaceutical compositions containing peptides, which are particularly suitable for sustained release of the API when administered to a patient. The present invention achieves this benefit and other benefits by providing a biodegradable liquid polymer pharmaceutical composition as follows: wherein the stability of the peptide drug is improved by selecting a suitable liquid polymer system (system), and in some embodiments, by further including a biocompatible solvent, or a combination or mixture of solvents and / or co-solvents and / or divalent cations in the composition. When the pharmaceutical compositions and formulations are provided using the liquid polymer system of the present invention, the peptide drug is advantageously maintained in a more stable chemical and physical form (e.g., showing less degradation due to acid degradation, acylation, etc.) during the manufacture, transportation and storage of the formulation, or in vivo in the patient's body and when exposed to the internal environment of the patient's body, according to the teachings provided herein, for a period longer than that achieved by the compositions of the prior art. Factors affecting stability may include at least the composition of the peptide, the composition of the liquid polymer, and the presence (and if present, identity and concentration) of divalent cations in the composition.

[0076] Therefore, the present invention includes biodegradable liquid polymer pharmaceutical compositions, which can be administered to the body using a syringe or needle, and are used to deliver medicines (active pharmaceutical ingredients, or API) and particularly peptides or other polymeric drugs to the body over an extended period of time. Such compositions can deliver API to patients at consistent levels within a therapeutic window for a long period of time to allow for improved ease of administration, thereby resulting in improved patient compliance to a dosing regimen. In particular, the present invention relates to liquid polymer pharmaceutical compositions and liquid polymer formulations, which include biodegradable polymers and active pharmaceutical ingredients (API) characterized as peptides (i.e., peptide drugs), and in some embodiments may further include divalent cations and / or solvents, or combinations or mixtures of solvents and / or cosolvents. The liquid polymer formulations of the present invention remain liquid (e.g., as discussed in detail herein, solid implants are not formed in vivo) after being administered to the body and remain stable over a wide temperature range for both polymers and API.

[0077] It has been unexpectedly discovered that in a liquid polymer delivery system comprising a biodegradable liquid polymer and a peptide drug comprising at least 1, 2, 3, 4, 5, 6, 7 or more accessible amine groups, the peptide is susceptible to degradation due to exposure to acidic groups and / or esters present on the liquid polymer, and such peptides can be stabilized by utilizing a biodegradable liquid block copolymer initiated by low molecular weight polyethylene glycol (PEG) and / or comprising a polymer block comprising low molecular weight PEG. The stability of the peptide drug can be further improved by the addition of divalent metal ions.

[0078] Further, it has been unexpectedly discovered that in a liquid polymer delivery system comprising a biodegradable liquid polymer and a peptide drug containing few, one or no accessible amine groups, the peptide drug can be stabilized by the addition of divalent metal ions.

[0079] The liquid polymer systems of the present invention do not undergo reverse thermogelation, that is, they are not reverse thermogels and do not have thermogel properties. Reverse thermogels are known and described in the prior art, for example, in U.S. Patent Nos. 6,201,072 to Rathi et al., U.S. Patent Application Publication No. 2007 / 0265356 to Kim et al., and U.S. Patent No. 9,901,554 to Bruin et al. (the entire contents of all of which are incorporated herein by reference). Reverse thermogels, or polymers having thermogel properties, can be most simply described as polymers that undergo a phase transition from a liquid at a lower temperature to a gel at a higher temperature when heated from a lower temperature to a higher temperature. In other words, as the temperature of the polymer solution increases, for example, above the gelation or phase transition temperature, the reverse thermogel spontaneously increases in viscosity and in many cases turns into a semisolid gel. Unlike reverse thermogel polymers, the liquid polymers of the present invention are not susceptible to phase transitions or viscosity increases due to temperature increases in a temperature range that at least spans room temperature and human body temperature, and the viscosity of such liquid polymer systems is substantially independent of temperature within this temperature range. Furthermore, the liquid polymer compositions of the present invention remain in liquid form in vivo, ie, do not form solid implants in vivo, even after the solvent has dissipated from the polymer upon exposure to an aqueous environment in the body.

[0080] In addition, polymers and copolymers with reverse thermal gelling properties are often referred to as "hydrogels" because such polymers are typically miscible or soluble in water below the temperature at which the gelling phase transition occurs. In contrast, the biodegradable liquid polymers of the present invention are not soluble in water.

[0081] As used herein, the term "accessible amine group" refers to an amine group that is open (for example, sterically open) and available for reaction with or nucleophilic substitution of the ester backbone of a polymer, or for acid-base reaction with an available acid group in a polymer.

[0082] As used herein, the term "animal" refers to any organism of the kingdom Animalia. Examples of "animals" as the term is used herein include, but are not limited to, humans (Homo sapiens); companion animals, such as dogs, cats, and horses; and livestock animals, such as cattle, goats, sheep, and pigs.

[0083] As used herein, the term "biocompatible" means "not harmful to living tissue."

[0084] As used herein, the term "peptide" means a polymer formed by covalently linking individual amino acids via the formation of peptide bonds. Peptides can be 2-39 amino acids in length and can be naturally occurring or synthetic in nature. In addition, peptides can be linear or cyclic in nature. Peptides can exist as independent compounds or be derived from larger proteins and can be unstructured in nature or display various levels of secondary protein structure, such as alpha-helices or beta-sheet folds. Peptides can have functional biological activity alone or in combination with additional binding partners.

[0085] As used herein, the term "biodegradable" refers to any water-insoluble material that is converted to one or more water-soluble materials under physiological conditions, without regard to any particular degradation mechanism or process. Water-insoluble polymers that are converted to one or more water-soluble materials under physiological conditions are referred to herein as "biodegradable polymers," and non-limiting examples of biodegradable polymers include polymers, copolymers, or terpolymers comprising lactide, glycolide, caprolactone, trimethylene carbonate, or dioxanone monomers.

[0086] As used herein, the term "liquid" refers to the ability of a composition (composition) to be continuously deformed under shear stress, regardless of whether there is a non-aqueous solvent. According to the liquid polymer composition of the present invention and liquid polymer have a liquid physical state at ambient temperature and body temperature and keep liquid in a largely aqueous environment in vivo. The liquid polymer composition and liquid polymer have a clear volume, but are amorphous, non-crystalline substances (mass) without a clear shape. In addition, the liquid polymer according to the present invention cannot be dissolved in body fluids or water and therefore, after being injected into the body and the solvent dissipates, it remains as a cohesive substance when being injected into the body and itself does not dissipate significantly. In addition, such liquid polymer compositions can have a viscosity, density and fluidity that allow the use of a standard syringe to deliver the composition using a low to medium injection force via a standard number or a small number needle (e.g., 18-26). The liquid polymer of the present invention may be further characterized in that when injected into the body as a part of a sustained-release drug delivery system comprising the liquid polymer and a biocompatible solvent or a combination or mixture of a solvent and / or a cosolvent, a solid implant is not formed in situ in the body. In other words, the liquid polymer according to the present invention is maintained in a substantially liquid form in situ when exposed to an aqueous environment, such as when injected into the body, after the solvent included in the composition administered has dissipated. The liquid polymer of the present invention may be further characterized by being non-crystalline, amorphous, non-thermoplastic, non-thermosetting, and / or non-solid. "Liquid", as the term is used in this article, may also exhibit viscoelastic behavior, i.e., viscosity and elastic properties, when undergoing deformation such as time-dependent and / or hysteresis strain. As a non-limiting example, generally flowable, but viscoelastic materials with partially gel-like shapes, such as cake batter or raw pizza dough, and similar materials are "liquids", as the term is used in this article. In some embodiments, a material with a non-zero yield stress that is not deformed under a stress below the yield stress and is easily deformable under a stress above the yield stress without the characteristic of material fracture or rupture may be a "liquid", as the term is used in this article.

[0087] As used herein, the terms "low molecular weight polyethylene glycol" and "low molecular weight PEG", unless otherwise specified, refer to polyethylene glycol (PEG) having a number average molecular weight of no more than 5,000 Daltons. In a block copolymer comprising both a PEG block and a block of one or more other monomers, if the number average molecular weight of the individual PEG blocks is no more than 5,000 Daltons, the PEG block may be referred to as a "low molecular weight polyethylene glycol" block or a "low molecular weight PEG" block, regardless of the number average or weight average molecular weight of the entire block copolymer.

[0088] As used herein, the terms "molecular weight" and "average molecular weight" may refer to number average molecular weight or weight average molecular weight. Typically, when referring to PEG blocks or PEG components herein, the number average molecular weight is used (e.g., PEG300 is a PEG with a number average molecular weight of 300 Daltons). Typically, when referring to copolymers (including di- or tri-block copolymers) herein, the weight average molecular weight is used. Reference to "number average molecular weight" or "M n " refers to the total number of molecules in a unit mass of polymer, and is calculated by dividing the total weight of the polymer by the total number of molecules. The "weight average molecular weight" or "Mw" depends not only on the number of molecules present, but also on the weight of each molecule. Thus, Mw is determined by methods that are sensitive to the size of molecules rather than just their number, such as light scattering techniques. As used herein, the weight average molecular weight of a polymer is the molecular weight as measured by a conventional gel permeation chromatography (GPC) instrument (e.g., Agilent 1260 Infinity Quaternary LC with Agilent G1362A refractive index detector) using polystyrene standards and using tetrahydrofuran (THF) as solvent.

[0089] As used herein, the terms "patient" and "subject" are interchangeable and generally refer to an animal to which a composition or formulation of the invention is or will be administered.

[0090] As used herein, the term "polymer" generally refers to polymers, copolymers and / or terpolymers that may be linear, branched, grafted and / or star-shaped. Non-limiting examples of polymers include polyglycolides, polylactides, polycaprolactones, polyanhydrides, polyorthoesters, polydioxanones, polyacetals, polyesteramides, polyamides, polyurethanes, polycarbonates, polyphosphazenes, polyketals, polyhydroxybutyrates, polyhydroxyvalerates, polyethylene glycols, polyesters, and polyalkylene oxalates, as well as copolymers or terpolymers comprising combinations of monomers thereof.

[0091] As used herein, the term "small molecule" means an organic compound having a molecular weight of less than 900 Daltons.

[0092] Unless otherwise specified, all ratios between monomers in the copolymers disclosed herein are molar ratios.

[0093] As used herein, the term "solvent" refers to a liquid that dissolves a solid or liquid solute, or refers to the liquid external phase of a suspension in which solid particles are dispersed.

[0094] Liquid polymer

[0095] The liquid polymer composition of the present invention includes a biodegradable liquid polymer. At room temperature (e.g., at about 25°C) to body temperature (e.g., at about 37°C) or higher, the liquid polymer remains in a liquid (flowable) form under a shear stress greater than zero and / or greater than the yield stress, i.e., undergoes continuous deformation, even after the solvent dissipates from the polymer composition, such as when the polymer composition is exposed to an aqueous or largely aqueous environment (e.g., in vivo). The properties of being a liquid are achieved by controlling the molecular weight of the polymer and selecting and ratioing the monomers. In addition, the liquid polymer may have a bulk viscosity before injection that allows the composition to be easily administered, and in some embodiments is effective for providing a desired sustained release curve of a bioactive agent from an implant material. Since the liquid polymer is liquid at room temperature, they allow a mixture or combination of a lower concentration of a biocompatible solvent or a solvent and / or a cosolvent to provide an injectable formulation in the composition compared to a polymer / solvent composition prepared with a solid polymer.

[0096] Examples of suitable liquid polymers that can be used in the present application include polylactic acid, polyglycolic acid, polylactide (D, L-lactide, D-lactide, L-lactide), polyglycolide, polycaprolactone, polyanhydride, polyamide, polyurethane, polyesteramide, polyorthoester, polydioxanone, polyacetal, polyketal, polycarbonate, polyphosphazene, polyhydroxybutyrate, polyhydroxyvalerate, polyalkylene oxalate, polyalkylene succinate, poly(malic acid), polyethylene glycol, hyaluronic acid, chitosan and chitosan, and copolymers, terpolymers, and combinations or mixtures of the above materials. In one embodiment, the liquid polymer is selected from polylactide, polyglycolide, polycaprolactone, poly(trimethylene carbonate), polydioxanone, copolymers thereof, terpolymers thereof, or any combination thereof. Preferred materials include those polymers, copolymers or terpolymers made with lactide, glycolide, caprolactone, p-dioxanone, trimethylene carbonate, 1,5-dioxepan-2-one, 1,4-dioxepan-2-one, ethylene oxide, propylene oxide, sebacic anhydride, and diketene acetal / diol, and lactic acid, having lower molecular weight and amorphous regions to limit crystallinity and subsequent solidification.

[0097] Non-limiting examples of suitable liquid polymers according to the present invention include: copolymers of D, L-lactide, D-lactide, L-lactide or glycolide and ε-caprolactone, wherein the molar ratio of lactide (or glycolide) / caprolactone ranges from about 90:10 to about 10:90; and copolymers of D, L-lactide, D-lactide, L-lactide or glycolide and trimethylene carbonate (TMC), wherein the molar ratio of lactide (or glycolide) / TMC ranges from about 90:10 to about 10:90. Typically, the liquid polymers and bulk polymer compositions of the present invention may have an intrinsic viscosity of 0.05-0.50 dL / g as measured in a 0.10 g / dL hexafluoroisopropanol solution at 25°C.

[0098] In some embodiments, the liquid polymer may be a copolymer comprising a first monomer selected from lactide (D, L-lactide, D-lactide, and / or L-lactide), glycolide, and a combination thereof, and a second monomer selected from caprolactone, TMC, and a combination thereof. In various further embodiments, the liquid copolymer may be a block copolymer comprising: a first block comprising a first monomer selected from lactide (D, L-lactide, D-lactide, and / or L-lactide), glycolide, and a combination thereof, and a second monomer selected from caprolactone, TMC, and a combination thereof; and a second block comprising polyethylene glycol (PEG).

[0099] In various embodiments of the composition, the biodegradable liquid polymer is a copolymer of two monomers having a molar ratio of any two integers X to Y, wherein X and Y are each at least about 10 and not more than about 90 and the sum of X and Y is 100. In various embodiments of the composition, the biodegradable liquid polymer is a copolymer of two monomers having a molar ratio of any two integers X to Y, wherein X and Y are each at least about 25 and not more than about 75 and the sum of X and Y is 100. In some embodiments, the lactide or glycolide monomer and the caprolactone and / or TMC monomer are present in a molar ratio of between about 5:95 and about 95:5, between about 10:90 and about 90:10, between about 20:80 and about 80:20, between about 25:75 and about 75:25, or between about 30:70 and about 70:30. As a non-limiting example, a first monomer of the two or more monomers may be selected from lactide, glycolide, and combinations thereof and a second monomer of the two or more monomers may be selected from caprolactone, TMC, and combinations thereof.

[0100] Other examples of suitable liquid polymers of the present invention include biodegradable liquid polymers comprising copolymers having lactide (including D, L-lactide, D-lactide, and / or L-lactide) and / or glycolide residues, wherein the molar percentage of lactide and / or glycolide residues is greater than about 5% and less than about 95%. In some embodiments, lactide and / or glycolide monomer residues are present in at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 90% of the total monomer residues of the copolymer. Other examples of suitable liquid polymers of the present invention include biodegradable liquid polymers comprising copolymers with caprolactone and / or trimethylene carbonate residues, wherein the caprolactone and / or trimethylene carbonate residues account for an amount greater than about 5% and less than about 95%. In some embodiments, caprolactone and / or trimethylene carbonate monomer residues are present in at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 90% of the total monomers of the copolymer. A variety of further embodiments include liquid polymers having a molar ratio of about 75:25D, L-lactide:ε-caprolactone and about 75:25D, L-lactide:trimethylene carbonate.

[0101] In various embodiments, the biodegradable liquid polymer of the present invention may include a polymer block comprising a low molecular weight polyethylene glycol (PEG). Further, the polymer may have a ratio of ethylene glycol monomer units to monomer units other than ethylene glycol (e.g., lactide, glycolide, caprolactone, TMC, and combinations thereof) between about 5:95 and about 35:65, between about 10:90 and about 30:70, or between about 15:85 and about 25:75. The ratio of ethylene glycol monomer units to monomer units other than ethylene glycol may range from any integer ratio to any other integer ratio in the range of about 1:99 to about 40:60. In some embodiments, the ratio of ethylene glycol monomer units to monomer units other than ethylene glycol is about 10:90, about 20:80, or about 30:70.

[0102] In various embodiments, the biodegradable liquid polymer can be formed using an initiator, and the initiator is selected to provide the desired structure and particularly the desired polymer block structure or terminal group structure to the biodegradable liquid polymer. As a non-limiting example, the polymer can be formed using a low molecular weight PEG as an initiator, which can lead to the formation of a block copolymer including a low molecular weight PEG block in various embodiments. As other non-limiting examples, the polymer can be formed using an organic acid such as a hydroxy acid such as glycolic acid, which can lead to the formation of a polymer including at least one carboxylic acid terminal group in various embodiments. As described in more detail in the following description and examples, whether alone or in combination with a selected divalent cation, the initiator can be selected to ensure that the peptide drug has improved stability in the formulation; as a non-limiting example, the polymer initiated by the low molecular weight PEG can be used with or without a divalent cation to stabilize a peptide with at least one accessible amine group, and the acid-initiated polymer can be used in combination with a divalent cation to stabilize a peptide with little or no accessible amine group.

[0103] Biodegradable liquid polymers of the present invention are not reverse thermogelling polymers. Reverse thermogelling polymers are polymers that are soluble in water at selected temperatures (e.g., room temperature or lower) and that undergo spontaneous phase transitions, i.e., viscosity increases as the temperature rises, to form physical gels at elevated temperatures (e.g., human body temperature). Different from reverse thermogels, biodegradable liquid polymers of the present invention have a viscosity that is substantially independent of temperature and / or does not spontaneously increase as the temperature rises, and can be kept liquid and / or flowable, particularly at room temperature and human body temperature. In some embodiments, the non-reverse thermogelling properties of biodegradable liquid polymers of the present invention can be achieved by providing a biodegradable liquid polymer with an end group that is not covalently modified (e.g., an aliphatic hydrocarbon group or an acyl group).

[0104] The biodegradable liquid polymer of the present invention may include a block copolymer comprising at least two (individual) polymer blocks A and B. As a non-limiting example, block A may include a first monomer residue selected from D, L-lactide, D-lactide, L-lactide, glycolide or a combination thereof and a second monomer residue selected from ε-caprolactone, trimethylene carbonate or a combination thereof. Block B includes a low molecular weight polyethylene glycol (PEG). The blocks may be arranged in any number or order (e.g., as a diblock copolymer AB or a triblock copolymer ABA or BAB). Such polymers are formed by initiating the first and second monomer residues with a low molecular weight PEG initiator. In some embodiments, the PEG block may include methoxy-PEG. In the block copolymer including the low molecular weight PEG block, the molar ratio of ethylene glycol monomer to all other monomers in the block copolymer can be at least about 5:95, or at least about 10:90, or at least about 20:80, or at least about 30:70, or at least about 40:60, or at least about 50:50, or any integer ratio in the range of about 1:99 to about 60:40. In one embodiment, the molar ratio of ethylene glycol monomer to all other monomers in the block copolymer can be between about 10:90 and about 50:50. As a non-limiting example, the molar ratio of the first monomer (e.g., lactide and / or glycolide) to the second monomer (e.g., caprolactone and / or TMC) to ethylene glycol in the entire polymer can be X:Y:Z, where X can be any number between about 25 and about 75, Y can be any number between about 5 and about 45, and Z can be any number between about 5 and about 55, such that the sum of X, Y, and Z is about 100. Table 1 illustrates non-limiting examples of such polymers.

[0105] The PEG may have any number average molecular weight between about 200 Daltons and about 5,000 Daltons. In some embodiments, the number average molecular weight of the PEG may be about 4,500 Daltons or less, or about 4000 Daltons or less, or about 3500 Daltons or less, or about 3000 Daltons or less, or about 2500 Daltons or less, or about 2000 Daltons or less. In some embodiments, the number average molecular weight of the PEG can be about 1,900 Daltons or less, or about 1,800 Daltons or less, or about 1,700 Daltons or less, or about 1,600 Daltons or less, or about 1,500 Daltons or less, or about 1,400 Daltons or less, or about 1,300 Daltons or less, or about 1,200 Daltons or less, or about 1,100 Daltons or less, or about 1,000 Daltons or less, or about 900 Daltons or less, or about 800 Daltons or less, or about 700 Daltons or less, or about 600 Daltons or less, or about 500 Daltons or less, or about 400 Daltons or less, or about 300 Daltons or less, or about 200 Daltons. In some embodiments, the molecular weight of the PEG can be about 900 Daltons or less, or about 800 Daltons or less, or about 700 Daltons or less, or about 600 Daltons or less, or about 500 Daltons or less, or about 400 Daltons or less, or about 300 Daltons or less.

[0106] Biodegradable liquid polymers suitable for use in formulations according to the present invention, including both PEG-initiated and acid-initiated polymers, may generally have a weight average molecular weight of any value in integer increments between about 1 kDa and about 40 kDa, or between about 1 kDa and about 35 kDa, or between about 1 kDa and about 30 kDa, or between about 1 kDa and about 25 kDa, or between about 1 kDa and about 20 kDa, or between about 1 kDa and about 40 kDa. In various embodiments, the polymer has a molecular weight of at least about 2 kDa, or at least about 3 kDa, or at least about 4 kDa, or at least about 5 kDa, or at least about 6 kDa, or at least about 7 kDa, or at least about 8 kDa, or at least about 9 kDa, or at least about 10 kDa, or at least about 11 kDa, or at least about 12 kDa, or at least about 13 kDa, or at least about 14 kDa, or at least about 15 kDa, or at least about 16 kDa, or at least about 17 kDa, or at least about 18 kDa, or a weight average molecular weight of at least about 19 kDa, or at least about 20 kDa, or at least about 21 kDa, or at least about 22 kDa, or at least about 23 kDa, or at least about 24 kDa, or at least about 25 kDa, or at least about 26 kDa, or at least about 27 kDa, or at least about 28 kDa, or at least about 29 kDa, or at least about 30 kDa, or at least about 31 kDa, or at least about 32 kDa, or at least about 33 kDa, or at least about 34 kDa, or at least about 35 kDa.

[0107] In various embodiments of the composition, the biodegradable liquid polymer may account for between about 0.1% and about 50% by weight of the composition, or between about 5% and about 45% by weight of the composition, or between about 10% and about 40% by weight of the composition, or between about 15% and about 35% by weight of the composition, or between about 20% and about 30% by weight of the composition, or about 20% by weight of the composition, or about 25% by weight of the composition, or about 30% by weight of the composition. Alternatively, the biodegradable liquid polymer may account for any integer weight percentage between about 1% and about 50% by weight of the formulation, or may account for any integer weight percentage of the formulation to any other integer weight percentage of the formulation and the range of endpoints between 1% and 50% by weight.

[0108] Solvent

[0109] Solvents and co-solvents that can be used in accordance with the present invention are biocompatible, non-toxic solvents that can be hydrophilic or hydrophobic, or can be hydrophilic, hydrophobic, or a combination of hydrophilic and hydrophobic solvents, depending on the desired release profile and solubility of the polymer and / or the bioactive agent in the polymer / solvent composition. Solvents and co-solvents suitable for use in various embodiments of the present invention include, by way of non-limiting example, acetone, benzyl benzoate, butyrolactone, ε-caprolactone, N-cyclohexyl-2-pyrrolidone, diethylene glycol monomethyl ether, dimethylacetamide, dimethylformamide, dimethyl sulfoxide (DMSO), ethyl acetate, ethyl lactate, N-ethyl-2-pyrrolidone, glycerol formal, ethoxylated tetrahydrofurfuryl alcohol, N-hydroxyethyl-2-pyrrolidone, isopropyl glycerol, lactic acid, methoxy polyethylene glycol, methoxypropylene glycol, methyl acetate, methyl ethyl ketone, methyl lactate, N-methyl-2-pyrrolidone ketone (NMP), low molecular weight (MW) polyethylene glycol (PEG), polysorbate 80, polysorbate 60, polysorbate 40, polysorbate 20, polyoxyl 35 hydrogenated castor oil, polyoxyl 40 hydrogenated castor oil, sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, benzyl alcohol, isopropyl alcohol, t-butyl alcohol, n-propyl alcohol, propylene glycol, 2-pyrrolidone, alpha-tocopherol, triacetin, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, triethyl citrate, furfural, its esters, and combinations thereof.

[0110] The biocompatible solvent, or combination or mixture of solvents and / or co-solvents used in the compositions of the present invention will typically comprise between about 20% and about 95% by weight of the formulation, or between about 35% and about 80% by weight of the formulation, or between about 45% and about 65% by weight of the formulation, or between about 45% and about 55% by weight of the formulation, or about 50% by weight of the formulation, or alternatively the solvent, or combination or mixture of solvents and / or co-solvents may range from any integer weight percentage of the formulation between about 20% and about 95% by weight to any other integer weight percentage of the formulation.

[0111] In one embodiment, the liquid polymer composition includes between about 20% and about 50% by weight of a biodegradable liquid polymer and between about 50% and about 70% by weight of a biocompatible solvent. The liquid polymer / solvent concentration allows the liquid polymer / solvent composition to be easily injected with a standard syringe and a small gauge needle (e.g., about 18-26 gauge). The compositions of the present invention can be administered to a human subject or other animal such as a dog, cat, horse, cow, goat, sheep, or pig.

[0112] Divalent metal ions

[0113] The pharmaceutical composition according to the present invention may further include a divalent metal ion or cation selected to improve the stability of the peptide drug in the pharmaceutical formulation. Typically, the divalent cation will be selected from alkaline earth metals and transition metals that typically have a +2 oxidation state, and most often will be selected from magnesium, calcium, and zinc. In various embodiments, the divalent cation may be provided as a metal salt, i.e., together with an anion; as a non-limiting example, the anion may be selected from acetate and chloride, and thus the metal salt may be an acetate or chloride of the selected metal (e.g., acetate or chloride of magnesium, calcium, or zinc). Since each divalent cation and / or metal salt may have a different effect on the stability of a specific peptide, the divalent cation and / or metal salt may be selected based on the peptide that is desired to be introduced into the formulation to provide enhanced stability, as further described in the following specification and examples.

[0114] The concentration of the metal salt comprising a divalent cation in the pharmaceutical composition can be selected based on various factors described herein, including, but not limited to, the stability-enhancing effect of the metal salt on the peptide of interest and pharmaceutically acceptable or pharmaceutically recommended limits for the concentration of the metal salt in the pharmaceutical composition.

[0115] As a first non-limiting example wherein the metal salt is magnesium acetate, magnesium acetate can have a concentration in the pharmaceutical composition of between about 0.01 mg / mL and about 2.75 mg / mL, or between about 0.25 mg / mL and about 2.5 mg / mL, or between about 0.5 mg / mL and about 2.25 mg / mL.

[0116] As a second non-limiting example, wherein the metal salt is magnesium chloride, the magnesium chloride can have a concentration in the pharmaceutical formulation of between about 0.01 mg / mL and about 3.75 mg / mL, or between about 0.6 mg / mL and about 3.15 mg / mL, or between about 1.2 mg / mL and about 2.55 mg / mL.

[0117] As a third non-limiting example, where the metal salt is calcium chloride, the calcium chloride can have a concentration in the pharmaceutical formulation of between about 0.01 mg / mL and about 1.6 mg / mL, or between about 0.4 mg / mL and about 1.2 mg / mL, or between about 0.75 mg / mL and about 0.85 mg / mL.

[0118] As a fourth non-limiting example wherein the metal salt is zinc acetate, zinc acetate can have a concentration in the pharmaceutical formulation of between about 0.01 mg / mL and about 8.2 mg / mL, or between about 1.05 mg / mL and about 6.75 mg / mL, or between about 2.1 mg / mL and about 5.7 mg / mL.

[0119] As a fifth non-limiting example, wherein the metal salt is zinc chloride, the zinc chloride can have a concentration in the pharmaceutical formulation of between about 0.01 mg / mL and about 1.4 mg / mL, or between about 0.05 mg / mL and about 1.2 mg / mL, or between about 0.1 mg / mL and about 1.05 mg / mL.

[0120] Drug administration

[0121] The liquid polymer and solvent composition with active pharmaceutical agent can be applied or injected into the body of the object using a device such as a syringe or needle, or an object (e.g., a net, a catheter, a screw, a plate, a tack, a pin, a staple, a sponge, etc.). The device with the composition can be placed in the body of the object. Suitable injection routes include, but are not limited to, any parenteral route, such as subcutaneous, intramuscular, intraarticular, and intradermal routes. Other routes of administration include, but are not limited to, topical administration, or sublingual administration (e.g., for membranes or similar systems). As a non-limiting example, when it is desired that the API acts locally rather than systemically, the liquid polymer formulation of the present invention can be administered to joint areas, skin areas, eye areas, and / or tumor site areas. An advantage of the formulation of the present invention is that, due to the liquid nature of the formulation, they form implants or depots that can be characterized as soft, ductile, non-rigid, and / or non-solid. Such formulations, when administered to, for example, joint areas or other areas where mobility or dexterity may be a problem, result in the formation of implants or reservoirs in vivo after administration that have the following physical properties: it allows the implant or reservoir to be better tolerated than, for example, a solid hard implant and has a much smaller effect on mobility. After injection or use, the solvent dissipates and leaves behind a liquid bolus (bolus, pill, mass) of polymer and active pharmaceutical agent. The liquid polymer component of the implanted polymer / solvent composition of the present invention will flow and fill the void left by the solvent when the solvent dissipates from the implanted material. The implanted liquid polymer material remains as a liquid with a fluctuating (flowable) consistency, so that it remains movable and compressible and gradually degrades in the subject's body over time. Since the liquid polymer is not soluble in body fluids or water, the bolus in body tissue is not dissipated by dissolving in body fluids, but remains as a cohesive substance.

[0122] The liquid polymer / solvent composition can be used as a sustained release composition to provide a delivery system in which a drug or other bioactive agent is added to the liquid polymer / solvent composition to form a liquid polymer pharmaceutical composition, which is then injected or administered to the body. Upon exposure to body fluids, the solvent dissolves or dissipates in aqueous tissue fluids leaving a more viscous liquid polymer for the release of the encapsulated or embedded active agent. Liquid polymer implants formed by the composition of the present invention through dissolution or dissipation of the solvent can be used to control the release of bioactive agents and have a low initial burst and sustained release of the drug.

[0123] The pharmaceutical composition according to the present invention can be provided as a component of a delivery system comprising a syringe, wherein the pharmaceutical composition is contained in the syringe. Therefore, such delivery systems are also within the scope of the present invention. In some embodiments, the syringe can be an automatic syringe.

[0124] The liquid polymer pharmaceutical compositions of the present invention have been found to release the drug in the patient over a surprisingly long period of time, release surprisingly high total amounts of drug and allow adjustment of the initial burst profile to achieve a high or low initial burst as desired. In various embodiments, the active pharmaceutical agent in the liquid polymer pharmaceutical compositions of the present invention is released in the patient (e.g., as determined by measuring serum levels of the agent in the patient) for greater than three days, greater than one week, greater than two weeks, greater than three weeks, greater than four weeks, greater than one month, greater than two months, greater than three months, greater than four months, greater than five months, greater than six months, greater than nine months, or greater than one year. Such agent levels may be at levels that have a pharmacological or therapeutic effect.

[0125] One embodiment of the present invention is a method of treating, providing therapy, curing, or preventing a disease, disorder, or other ailment by administering a liquid polymer pharmaceutical composition comprising an active pharmaceutical agent, as described in detail elsewhere herein. These methods can be used to treat, provide therapy, cure, or prevent a microbial infection or any other infection caused by a pathogen, an autoimmune disorder, allergy, inflammation, cancer, endocrine disorder, metabolic disorder, neurological disorder, motor disorder, psychological disorder, cardiovascular disorder, or any other disease, disorder, or other ailment treated by an active pharmaceutical agent described herein.

[0126] Peptides

[0127] Active pharmaceutical agents (e.g., peptide drugs) suitable for use in the present application are biologically active agents that provide a biological effect and act locally or systemically in the treatment, therapy, cure and / or prevention of a disease, disorder, or other ailment. Examples of drugs include the following without limitation: peptide drugs, such as peptides, polypeptides, or proteins. Examples of peptide and polymer-based drugs suitable for use in the present application include degarelix, abaparatide, teriparatide, leuprorelin, dulaglutide, basal insulin, goserelin, triptorelin, nafarelin, buserelin, histrelin, deslorelin, ganirelix, abarelix, teverelix, lanreotide, carfilzomib, human growth hormone, interferon alpha, interferon beta, interferon gamma, interleukin, growth hormone-releasing peptide, glucagon-like peptide, granulocyte colony-stimulating factor, nerve growth factor, platelet-derived growth factor, insulin-like growth factor, vascular endothelial growth factor, fibroblast growth factor, octreotide, bone morphogenetic protein, erythropoietin, albiglutide, anaritide, angiotensin II, buforin II, calcitonin, carperitide, cecropin P1, cetrorelix, dermaseptin, desmopressin, drosocin, enfuvirtide, etelcalcetide, exenatide, indolicidin, liraglutide e), lixisenatide, magainin I, magainin II, nesiritide, neurotensin, pramlintide, ranalexin, semaglutide, tachyplesin, teduglutide, vasopressin, 1-deamino-8-D-arginine vasopressin, and salts, complexes, prodrugs, and analogs thereof.

[0128] A suitable drug that can be used in the present invention is abaloparatide. Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug that has attracted interest as a potential treatment for osteoporosis. Like the related drug teriparatide, but unlike bisphosphonates, abaloparatide is an anabolic (i.e., bone growth) agent. Various other embodiments of the present invention include liquid polymer pharmaceutical compositions of abaloparatide and its use in treating osteoporosis by administering to patients with osteoporosis in various amounts and various dosage schedules and routes of administration as disclosed elsewhere herein (which may include, without limitation, intermittent doses as needed and prescribed by a physician).

[0129] Another suitable drug that can be used in the present invention is leuprolide or an acceptable salt thereof. Leuprolide, also known as leuprolide, is a gonadotropin-releasing hormone analog (also known as a luteinizing hormone-releasing hormone (LHRH) agonist) that has been used in the treatment of various forms of cancer, particularly prostate cancer and breast cancer, as well as endometriosis, uterine fibroids, and central precocious puberty (CPP), as non-limiting examples. For example, treatment of advanced prostate cancer with leuprolide acetate may consist of a 7.5 mg subcutaneous dose administered monthly, a 22.5 mg subcutaneous dose administered every 3 months, a 30 mg subcutaneous dose administered every 4 months, or a 45 mg subcutaneous dose administered every 6 months. For example, treatment of endometriosis with leuprolide acetate may consist of a 3.75 mg subcutaneous dose administered monthly for up to 6 months, or two 11.25 mg doses administered at 3 month intervals. For example, treatment of uterine fibroids with leuprolide acetate may consist of monthly intramuscular doses of 3.75 mg for up to 3 months, or a single intramuscular dose of 11.25 mg. Various other embodiments of the invention include liquid polymer pharmaceutical compositions of leuprolide or its esters and their use in the treatment of cancer (including prostate and breast cancer), endometriosis, uterine fibroids, or CPP by administering to a patient in need thereof in the amounts and dosage schedules and routes of administration as disclosed elsewhere herein.

[0130] Various embodiments of the present invention include pharmaceutical compositions in which a peptide drug comprising at least one accessible amine group (e.g., arginine, histidine, lysine, N-terminus, etc.) is stabilized by utilizing a biodegradable liquid polymer initiated by low molecular weight PEG and / or comprising low molecular weight PEG blocks, alone or in combination with divalent cations. Without wishing to be bound by theory, it is believed that PEG initiated polymers may hinder acylation of accessible amine groups relative to, for example, acid initiated or dodecanol initiated polymers. Peptides used in these embodiments may include any peptide comprising an N-terminal amine group and / or any natural or unnatural amino acid comprising an accessible amine group; such amino acids include, but are not limited to, arginine, histidine, lysine, L-2-amino-3-guanidinopropionic acid, 4-guanidinobutyric acid, Fmoc-Lys(Me,Boc)-OH, Fmoc-Lys(Me)3-OH chloride, Fmoc-Lys(palmitoyl)-OH, and DL-5-hydroxylysine hydrochloride. In some embodiments, the peptide drug may include at least two accessible amine groups. In some embodiments, the peptide drug may include at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids selected from arginine, histidine, lysine, L-2-amino-3-guanidinopropionic acid, 4-guanidinobutyric acid, Fmoc-Lys(Me,Boc)-OH, Fmoc-Lys(Me)3-OH chloride, Fmoc-Lys(palmitoyl)-OH, and DL-5-hydroxylysine hydrochloride, and combinations thereof, and may additionally have an N-terminal amine group.

[0131] Thus, peptides with accessible amine groups suitable for use in these embodiments may include, but are not limited to, abaparatide, albiglutide, anaritide, angiotensin II, buforin II, calcitonin, caperitide, cecropin P1, cetrorelix, dermaseptin, desmopressin, drosophilin, enfuvirtide, etkadote, exenatide, indopenicillin, liraglutide, lixisenatide, magainin I, magainin II, nesiritide, neurotensin, pramlintide, bullfrog dermatospermide, semaglutide, tadalafil, teduglutide, teriparatide, vasopressin, 1-desamino-8-D-arginine vasopressin, and pharmaceutically acceptable esters, salts, complexes, prodrugs, and analogs thereof.

[0132] Various embodiments of the present invention include pharmaceutical compositions in which peptide drugs comprising few or no accessible amine groups are stabilized by utilizing a biodegradable liquid polymer initiated by an organic acid (e.g., a hydroxy acid such as glycolic acid) and / or comprising a carboxylic acid terminal group in combination with a divalent cation. Peptides suitable for use in these embodiments may include, but are not limited to, linear peptides (e.g., leuprolide), cyclic peptides (e.g., lanreotide, octreotide), and pharmaceutically acceptable esters, salts, complexes, prodrugs, and analogs thereof, and which have few, one, or no accessible amine groups.

[0133] The concentration of the active pharmaceutical agent in the composition of the present invention depends on the drug included in the composition and can range from 0.1% to 50% by weight of the composition, including any integer percentage in the range of about 1% to about 50% by weight to any other integer percentage. In some embodiments, the concentration of the active pharmaceutical agent is no greater than about 25% by weight. Typically, for a peptide drug product, the concentration of the agent in the composition is between about 0.1% and about 15% by weight of the composition, or between about 0.1% and about 14% by weight of the composition, or between about 0.1% and about 13% by weight of the composition, or between about 0.1% and about 12% by weight of the composition, or between about 0.1% and about 11% by weight of the composition, or between about 0.1% and about 10% by weight of the composition, or between about 0.1% and about 9% by weight of the composition, or between about 0.1% and about 8% by weight of the composition, or between about 0.1% and about 7% by weight of the composition, or between about 0.1% and about 6% by weight of the composition, or between about 0.1% and about 5% by weight of the composition, or between about 0.1% and about 4% by weight of the composition, or Between about 0.1% and about 3% by weight of the composition, or between about 0.1% and about 2% by weight of the composition, or between about 0.1% and about 1% by weight of the composition, or between about 0.1% and about 0.9% by weight of the composition, or between about 0.1% and about 0.8% by weight of the composition, or between about 0.1% and about 0.7% by weight of the composition, or between about 0.1% and about 0.6% by weight of the composition, or between about 0.1% and about 0.5% by weight of the composition, or between about 0.1% and about 0.4% by weight of the composition, or between about 0.1% and about 0.3% by weight of the composition, or between about 0.1% and about 0.2% by weight of the composition, including any increment of 0.01% by weight between about 0.1% and about 15% by weight of the composition. In various other embodiments, the amount of active pharmaceutical agent in the compositions of the present invention may range from any part per thousand to any other part per thousand within the range of about 0.1% to about 50% by weight.

[0134] Since the beneficial property of the composition disclosed herein is the improved sustained release of the active pharmaceutical agent, the amount of the active pharmaceutical agent will be suitable for long-term treatment using the agent according to the time frame disclosed herein. Various other embodiments of the present invention include single-dose formulations of the following liquid polymer pharmaceutical composition: it includes a liquid polymer composition as described herein and an active pharmaceutical agent suitable for the amount of sustained release. For example, such single-dose formulations may include an active pharmaceutical agent sufficient to treat a patient for more than 3 days, more than 1 week, more than 2 weeks, more than 3 weeks, more than 4 weeks, more than 1 month, more than 2 months, more than 3 months, more than 4 months, more than 5 months, more than 6 months, more than 9 months, or more than 1 year. The composition can be repeatedly given (e.g., every month, every 3 months, every 6 months, etc.) as needed.

[0135] The active drug agent can be the form of liquid or finely divided solid dissolved or dispersed in the liquid polymer / solvent composition. The agent is introduced into the composition in an amount sufficient to realize the desired therapeutic effect, the desired release curve and the desired release period. There is no strict upper limit for the amount of the agent dispersed or dissolved in the liquid polymer / solvent solution, as long as the solution has an acceptable fluid viscosity for injection by a standard or small syringe needle (e.g., No. 18-26) at room temperature. The lower limit of the amount of the agent introduced into the liquid polymer / solvent solution depends on the activity of the agent, the desired release rate for the desired treatment level and the time (time) length (degree) for the treatment of. Soluble and insoluble active drug agents can be introduced into the liquid polymer / solvent system.

[0136] The liquid polymer / solvent composition comprising an active pharmaceutical agent according to the present invention may suitably be a "solution" or "dispersion" or "suspension" of the active pharmaceutical agent in the biodegradable polymer and solvent. In particular, it is understood that while the liquid polymer is dissolved in the solvent, the active pharmaceutical agent may be dissolved in the polymer and solvent (e.g., in solution form) or form solid particles large enough to suspend and settle as part of a multiphase mixture (e.g., in suspension form).

[0137] The composition may include various adjuvants or additives, such as colorants, diluents, carriers, excipients, buffers, antioxidants, crystallization inhibitors, pH adjusters, and stabilizers.

[0138] The inventors have found that the stability of peptide drugs is significantly improved in compositions containing a liquid polymer delivery system according to the present invention that includes a biodegradable liquid polymer. As described herein, stability can be significantly improved over the stability obtained when using similar liquid polymer delivery systems that differ in the identity of the initiator end groups of the biodegradable liquid polymer, and stability can be significantly improved by including divalent cations such as metal salts in the liquid polymer delivery system.

[0139] The present inventors have found that by using a low molecular weight polyethylene glycol (PEG) initiator to initiate a biodegradable liquid polymer, the stability of a peptide drug comprising an accessible amine group in a composition comprising a biodegradable liquid polymer according to a liquid polymer delivery system of the present invention is significantly improved. The low molecular weight PEG is introduced into the resulting biodegradable liquid polymer as a polymer block to form a block copolymer. The present inventors have further found that the stability of the peptide drug can, but need not be, further improved by including a divalent metal cation selected from magnesium, calcium or zinc in the composition, and / or a metal salt selected from magnesium chloride, calcium chloride, and zinc acetate.

[0140] The present inventors have found that the stability of linear peptide drug substances comprising few or no accessible amine groups in a composition of a liquid polymer delivery system according to the present invention comprising a biodegradable liquid polymer is significantly improved by including in said composition a divalent metal cation and / or a metal salt, and in particular a divalent metal cation selected from magnesium and zinc and / or a metal salt selected from magnesium acetate, zinc chloride, and zinc acetate.

[0141] The present inventors have found that the stability of cyclic peptide drug substances comprising few or no accessible amine groups in a composition of a liquid polymer delivery system according to the present invention comprising a biodegradable liquid polymer is significantly improved by including divalent metal cations and / or metal salts, and in particular divalent zinc cations and / or metal salts selected from zinc chloride and zinc acetate in said composition.

[0142] The invention is illustrated by the following non-limiting examples.

[0143] Example

[0144] Embodiment 1: Methods of forming LPT formulations comprising peptides

[0145] The following examples describe methods for preparing and testing Liquid Polymer Technology (LPT) formulations including various peptide molecules, and also describe the manufacture and properties of a large group of PEG-initiated liquid polymers according to the present invention.

[0146] LPT polymer

[0147] To make the LPT formulations described in Examples 1-10 below, exemplary LPT polymers were made using one of three different initiators. Specifically, the LPT polymers were initiated as follows: 1) using glycolic acid as the initiator (i.e., "acid-initiated polymers"), 2) using dodecanol as the initiator (i.e., "dodecanol-initiated polymers"), or 3) using low molecular weight polyethylene glycol (PEG) (i.e., "PEG-initiated polymers").

[0148] For example, in order to make poly-(D, L-lactide-ε-caprolactone) (PDLCL) liquid copolymer, D, L-lactide, ε-caprolactone and selected initiator are provided with the amount calculated to achieve the target composition molar ratio and target weight average molecular weight. In brief, a 500mL 2-part glass reactor equipped with a nitrogen inlet, an overhead stirrer with a vacuum-capable stir guide and a vacuum outlet to a vacuum trap and a vacuum pump is assembled and placed in an oil bath. The oil bath is set to 100°C and the reactor is placed under vacuum to remove any residual moisture.

[0149] For polymer compositions initiated with acid initiators or dodecanol, the vacuum on the reactor was broken with nitrogen and the specified amount of D, L-lactide, initiator, and ε-caprolactone was added to the reactor via a glass funnel. For polymer compositions initiated with PEG, PEG was added to the reactor before adding D, L-lactide and ε-caprolactone, and the vacuum was purged to remove moisture from the PEG. After this step, the vacuum on the reactor was broken with nitrogen and the specified amount of D, L-lactide and ε-caprolactone was added to the reactor. For all three polymer compositions, at this stage, the agitator was turned on to 10-50 rpm, the oil bath was set to 160°C, and the system was vacuum purged and backwashed 3 times with nitrogen. The reactor was then placed under a slight nitrogen purge.

[0150] Catalyst solution is prepared as follows: weigh an appropriate amount of 2-ethylhexanoic acid tin (II) (stannous octoate) and place it in a 10mL volumetric flask and dilute to the mark with anhydrous toluene. For all polymer compositions described in these embodiments, once the monomer has melted and the oil bath reaches 160°C, typically 5mL of catalyst solution is injected via a syringe equipped with a 6-inch blunt shuttle tip 20G needle under continuous stirring, and its amount is calculated to achieve a 0.03 wt % catalyst solution based on monomer weight. For example, for a 400gm batch of polymer, the amount of catalyst solution required for adding 0.03 wt % stannous octoate based on monomer weight is calculated as 0.12g (in 5mL toluene). For example, for a 500gm batch of polymer, the amount required for adding 0.03 wt % stannous octoate based on monomer weight is calculated as 0.15g (in 5mL toluene).

[0151] After the injection (injection) of the catalyst solution, the polymerization reaction is continued for 16-18 hours. After the suitable reaction time, the vacuum trap is immersed in an ice bath and the nitrogen inlet is closed. Vacuum is slowly applied to the stirred reaction mixture for 4-6 hours, and the final vacuum is -22 to -25 inches Hg. Unreacted monomers are collected in the vacuum trap. After the suitable time, the vacuum is stopped, the reactor is purged with nitrogen, removed from the oil bath and the liquid polymer is poured into a metal, glass or (low thermal expansion plastic borosilicate glass) container and cooled. For all polymer compositions, the yield was about 85%.

[0152] The weight average molecular weight of the polymer is determined by gel permeation chromatography (GPC) with a refractive index detector (eg, Agilent 1260 Infinity Quaternary LC with Agilent G1362A refractive index detector).

[0153] Table 1 describes 17 different liquids, which are PEG-initiated block copolymers of the present invention, which are manufactured to have a variety of monomer molar ratios and target weight average molecular weights. The polymers described in Table 1 are each block copolymers having an ABA structure, where "A" is a poly (D, L-lactide-ε-caprolactone) copolymer and "B" is a low molecular weight PEG (a variety of different low molecular weight PEG initiators are exemplified). The molar ratio of D, L-lactide to ε-caprolactone in each polymer is approximately 75:25. When different batches of monomers are used, or when different initiators are used, the exact amounts of monomers and initiators may vary, and the appropriate amounts to achieve a given target molar ratio and molecular weight can be calculated by one skilled in the art using the guidelines provided herein. For each of the biodegradable, liquid, PEG-initiated block copolymers described in Table 1, the table provides: (1) the number of moles of D,L-lactide in the copolymer; (2) the number of moles of ε-caprolactone (CL) in the copolymer; (3) the identity of the specific low molecular weight PEG initiator (Initiator); (4) the number of moles of PEG in the copolymer (and the number of moles of ethylene glycol (EG) in the copolymer); (5) the mole percentage of D,L-lactide:ε-caprolactone:EG monomers (DL:CL:EG) in each copolymer; (6) the number of moles of D,L-lactide in each copolymer. and the molar ratio of ε-caprolactone monomer to EG monomer ((DL+CL / EG); (7) and the weight average molecular weight of the final block copolymer (kDa). In addition, for each of the block copolymers in Table 1, as shown in the table, in particular, all are "liquid" polymers as defined herein (physical form), meaning that the polymers remain in liquid form as defined herein even after injection and solvent dissipation, all are insoluble in water (water solubility), and all have no thermal gelling properties (thermogel properties). Selected PEG-initiated copolymers from Table 1 were used in the following examples.

[0154] The acid-initiated polymer used in the following examples is a glycolic acid-initiated, 75:25 poly (DL-lactide-co-ε-caprolactone) (PDLCL) liquid polymer (i.e., a polymer composed of 75% DL-lactide and 25% ε-caprolactone (mol:mol)), having various molecular weights as shown in the various examples. For example, a 75:25 acid-initiated PDLCL copolymer having a weight average molecular weight of approximately 5 kDa can be made using 2.2 moles of D, L-lactide and 0.73 moles of ε-caprolactone, initiated with 0.42 moles of glycolic acid. When different batches of monomers are used, or when different initiators are used, the exact amounts of monomers and initiators may vary, and one skilled in the art can calculate the appropriate amounts to achieve a given target molar ratio and molecular weight.

[0155] The dodecanol-initiated polymers used in the following examples are all dodecanol-initiated, 75:25 poly (DL-lactide-co-ε-caprolactone) (PDLCL) liquid polymers (i.e., polymers composed of 75% DL-lactide and 25% ε-caprolactone (mol:mol)), having various molecular weights as shown. For example, a 75:25 dodecanol-initiated PDLCL copolymer having a weight average molecular weight of approximately 4 kDa can be made using 1.65 moles of D, L-lactide and 0.55 moles of ε-caprolactone, initiated with 0.18 moles of dodecanol. As discussed above, when different batches of monomers are used, or when different initiators are used, the exact amounts of monomers and initiators may vary, and one skilled in the art can calculate the appropriate amounts to achieve a given target molar ratio and molecular weight.

[0156]

[0157] LPT polymer solution . An LPT polymer solution containing about 40% w / w of various LPT polymers was combined with about 60% w / w of the solvent N-methyl-2-pyrrolidone (NMP). For example, for three PDLCL polymers in which the molar ratio of D,L-lactide and ε-caprolactone was 75:25 used in some of the embodiments herein, Table 2 provides the relative amounts of the polymer and the solvent N-methyl-2-pyrrolidone (NMP). In the case of the PEG300-initiated polymer, the molar ratio of D,L-lactide to ε-caprolactone to ethylene glycol was about 49.3:18.2:32.6 (see Table 1, Sample No.12). The solution was prepared as follows: the materials were weighed into a 100 g FlackTek jar and mixed using a roller mixer. The solution was mixed overnight and checked for any lumps using a spatula. Continue mixing until the solution is uniform and free of lumps. The solutions were stored at 5°C until they were ready to be loaded with the peptide active ingredient.

[0158] Table 2

[0159]

[0160] LPT Formulations. LPT polymer-peptide formulations were prepared by adding the peptide and polymer solution (i.e., the copolymer of the present invention in combination with a solvent) to a 20 mL or 40 mL tube, as appropriate, and by mixing the contents with a vortex mixer for 30 seconds. For each of the LPT polymer-peptide formulations described in these examples, the peptide was added to the formulation at between about 0.3% and 0.5% w / w. For each LPT polymer-peptide formulation, the stability of each sample was tested at the target storage time as outlined in the following examples.

[0161] In the examples described below, LPT polymer-peptide formulations were prepared including: (1) approximately 40% w / w of a 75:25 poly(DL-lactide-co-ε-caprolactone) (PDLCL) liquid polymer having the indicated molecular weight and made using the indicated initiator; (2) approximately 60% w / w of N-methyl-2-pyrrolidone (NMP); and (3) between about 0.3% and about 0.5% of a peptide as indicated.

[0162] In order to prepare LPT-peptide formulations including divalent metal salts, a mixture of peptide and corresponding metal salt solution is prepared and lyophilized. The lyophilized peptide / metal salt mixture is then combined with the LPT polymer solution. In short, first, the peptide is mixed with a certain concentration of metal salt solution in water. The solution (based on amount) is fully mixed using a vortex or stirring plate until all peptides are fully dissolved. For example, the preparation of sample AA1 in Example 4 below involves preparing a solution of 1.3 mg / mL magnesium chloride in water, after which approximately 30 mg of abaloparatide acetate is added to 12 mL of 1.3 mg / mL magnesium chloride solution in a 20 mL scintillation tube, then vortexed until all peptides are dissolved in the metal salt solution. After this step, the mixture of peptide and metal salt solution is lyophilized by freeze drying technology. The peptide content is determined by analysis of the lyophilized peptide / metal salt mixture (lyophilized cake) using reverse phase ultra-high performance liquid chromatography (RP-UHPLC) and the actual required amount of the lyophilized peptide / metal salt mixture is calculated to provide the desired amount of peptide in the formulation (e.g., see sample AA1 in Example 4, 5 mg of abalaparatide acetate per 1 g of final LPT-peptide formulation, i.e., 0.5% w / w peptide in the formulation). Finally, the desired amount of lyophilized peptide / metal salt is weighed into a 20 mL scintillation vial and mixed with an appropriate amount of LPT polymer solution. For example, approximately 7.5 mg of lyophilized peptide / metal salt (e.g., a 2:1 peptide:metal salt weight ratio as shown in Table 4 for sample AA1) is added to approximately 992.5 mg of polymer solution to form an LPT polymer solution.

[0163] Embodiment 2: LPT formulations comprising abaparatide acetate and LPT liquid polymers initiated with different polymer initiators

[0164] This example demonstrates that the stability of abaloparatide is improved in LPT formulations including PEG-initiated LPT polymers compared to LPT formulations including acid- or dodecanol-initiated LPT polymers.

[0165] Abaparatide acetate (AA) is an exemplary peptide having at least one accessible amine group according to the present invention. Specifically, AA has 7 accessible amine groups in the form of 4 accessible lysine groups and 3 accessible arginine groups in the peptide, as well as an N-terminus. LPT polymer-abaparatide acetate formulations were prepared according to the procedure outlined in Example 1. In this example, the LPT polymer in all cases was a copolymer of D,L-lactide and ε-caprolactone ("PDLCL") having a lactide to caprolactone molar ratio of about 75:25 or 25:75 as shown, wherein the copolymer was initiated with the indicated initiator (see Table 3). In the case of the PEG300 initiated copolymer, the lactide to caprolactone to ethylene glycol ratio was about 57:21.3:21.7 (see Table 1 Sample No. 9). All formulations included NMP as a solvent in an amount to give a copolymer to solvent weight ratio of about 40:60. In each formulation, about 5 mg of abaparatide acetate peptide was combined with about 1000 mg of LPT polymer solution (eg, approximately 0.5% w / w peptide in the formulation).

[0166] For stability testing, samples were incubated in an oven at 25°C until the target storage time was reached and at this time, a single sample of a given LPT polymer-abaparatide acetate formulation was removed from the incubator and tested for abaloparatide acetate content.

[0167] Prior to testing, the sample was allowed to stand so that the sample temperature reached room temperature and the tube was vortexed for about 60 seconds before extraction. For sample analysis, 2.0 mL of 50:50 acetonitrile / methanol was carefully transferred to a scintillation vial and the lid was returned to place, vortexed for 1 minute, and then sonicated for 2 minutes. 15.0 mL of 65:35 water / methanol was added to the same scintillation vial, the lid was returned to place and vortexed again for 1 minute, and then sonicated for 2 minutes. After discarding the first ~1 mL aliquot, the sample was filtered through a 0.2 μm polytetrafluoroethylene (PTFE) filter into a high performance liquid chromatography (HPLC) tube. The sample was analyzed by reverse phase ultra-high performance liquid chromatography (RP-UHPLC) using a standard peptide determination method. In the later examples described herein, in order to analyze samples with peptides other than abalaparatide acetate, double dilution was used to adjust the sample concentration based on the absorbance of the peptide; therefore, the assay can be adapted to the peak intensity using the same method parameters.

[0168] The results of the stability testing are provided in Table 3, which shows (1) the molecular weight of the copolymer used in each of the formulations, (2) the molar ratio of D,L-lactide (DL) to ε-caprolactone (CL) monomers, (3) the initiator used to form the liquid copolymer, and (4) with respect to stability (i.e., in storage), the percent recovery (w / w) of abaloparatide acetate from the LPT-ababaloparatide acetate formulations after a given number of days.

[0169] Table 3

[0170]

[0171] Figure 1 Results of stability testing of various LPT polymer-abaparatide acetate formulations (AAX1-AAX4) at 25°C are shown. The results show that the stability of abalaparatide acetate (measured by the percentage w / w recovery of peptide from the formulation) is higher in PEG-300 initiated polymers (AAX3, ▲) than in formulations prepared using acid initiated polymers (AAX1, ◆=25:75 acid initiated PDLCL; AAX2, ■=75:25 acid initiated PDLCL) or dodecanol initiated polymers (AAX4, ●). For the PEG-300 initiated polymer, the percentage recovery of abalaparatide after 9 days at 25°C was about 19%, while essentially all of the abalaparatide had degraded in the acid initiated and dodecanol initiated polymers. The two acid initiated polymers with different D,L-lactide to ε-caprolactone monomer ratios (75:25 or 25:75) showed similar peptide recovery curves.

[0172] These results show that abaparatide can be stabilized in PEG-initiated LPT polymer formulations relative to acid-initiated and dodecanol-initiated LPT polymer formulations.

[0173] Embodiment 3: Mechanism of peptide degradation of LPT formulations including peptides with accessible amine groups

[0174] This example illustrates that the peptide degradation observed in the LPT polymer formulation including abaparatide acetate in Example 2 was due to acylation resulting in the addition of a lactoyl fragment to abaparatide.

[0175] Liquid chromatography-mass spectrometry (LC-MS) and HPLC were used to identify the degradation products and mechanism of abaparatide acetate in the presence of the acid-initiated and PEG-300-initiated LPT polymers (75:25 PDLCL) of Example 2. For each LPT polymer, data were collected for freshly prepared samples (0 days storage time) and samples that had been incubated at 25°C for 2 days in the case of the acid-initiated LPT polymer and 3 days in the case of the PEG-300-initiated polymer.

[0176] Figure 2A and 2B Zoomed portions of HPLC chromatograms showing acid initiated LPT polymer-abaparatide acetate formulations at 25°C at 0 and 2 days, respectively. A strong signal for abalaparatide acetate was observed at approximately 12.5 minutes. The chromatograms collected for the aged (2 days) formulations showed that the degradant peak eluting immediately after abalaparatide acetate was a result of peptide acylation, which was also supported by the LC-MS / MS results (data not shown). An increase of 144 Da was observed in the LC-MS / MS chromatograms, leading to the hypothesis that acylation (+72 Da) may be occurring at some combination of the N-terminus, arginine, and / or lysine groups of abalaparatide. Acylation was found to be caused by interaction with the lactide monomer of the PDLCL copolymer, resulting in the addition of the lactoyl fragment to abalaparatide. This was found to be the primary degradation mechanism occurring for the abalaparatide formulation. The 2-day-old samples showed strong evidence that abaloparatide was modified 1-6 times (mostly even numbers) with lactide. The exact locations of the modifications occurring on abaloparatide were not investigated in more detail.

[0177] Similar experiments were performed for PEG-300 initiated LPT polymer-abaparatide acetate formulations at 25°C at 0 and 3 days. The analysis showed a similar acylation pattern to abaloparatide, with an increase of 72 Da corresponding to the lactoyl fragment (data not shown). However, it was observed that the abundance of acylated species in the PEG300 initiated polymer samples was significantly lower than that observed in the acid initiated polymer samples. This is consistent with the stability observed for the PEG-300 initiated LPT polymer-abaparatide acetate formulations at 25°C (percent recovery curves) relative to the increased stability observed for the acid initiated formulations in Example 2 (see Table 3).

[0178] Embodiment 4: LPT formulations comprising abaparatide acetate and a divalent metal salt

[0179] This example demonstrates that the stability of abaparatide acetate is further improved by the addition of divalent metal ions in LPT formulations including PEG-initiated LPT polymers.

[0180] LPT polymer-abaparatide formulations with and without metal chloride salts were prepared according to the procedure outlined in Example 1. In this example, the copolymer used for all formulations was a PEG300 initiated PDLCL copolymer having a molar ratio of lactide to caprolactone of about 75:25, and a ratio of lactide-caprolactone-ethylene glycol of about 57:21.3:21.7, an average molecular weight of 7.9 kDa (see, e.g., Table 1, Sample No. 9). The formulations included NMP as a solvent in an amount that resulted in a polymer to solvent weight ratio of about 40:60. To prepare LPT-peptide formulations including a divalent metal salt, a mixture of acetate abalaparatide peptide and the corresponding metal salt as a solution was prepared (see Table 4) and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 5 mg acetate abalaparatide peptide relative to about 1000 mg LPT polymer solution (e.g., approximately 0.5% w / w peptide in the formulation).

[0181] For accelerated stability testing, samples were incubated at 37°C until the target storage time was reached. Samples were analyzed according to the procedure outlined in Example 2 for recovered abaloparatide acetate content in % w / w.

[0182] The results of the stability testing for formulations AA1-AA3 including metal salts, and control formulation AAX8 without metal salts are provided in Table 4. Table 4 shows (1) the metal salts used, (2) the concentration of the metal salt solution in the final formulation (mg / mL), (3) the weight / weight ratio of abaparatide acetate to metal salt in the final formulation (peptide:metal salt ratio), and (4) the percent recovery of abaparatide acetate from the LPT polymer-ababaparatide acetate formulations (% w / w) after storage at 37°C for a given number of days.

[0183] Table 4

[0184] Formulation ID AAX8 AA1 AA2 AA3 Metal Salts none Magnesium chloride Calcium chloride Zinc chloride Salt concentration (mg / mL) N / A 1.25 0.8 0.38 Peptide:metal salt ratio N / A 2∶1 6∶1 13∶1 % Recovery at 0 Days 92.1 96.6 95.6 94.6 % Recovery at 1 Day 77.1 97.6 99.1 90.7 % Recovery at 3 days 13.0 92.3 89.2 73.1 % Recovery at 7 days 0.0 88.4 73.6 46.1 % Recovery at 21 days 0.0 81.9 22.2 0.0

[0185] Figure 3Results of recovery tests at 37°C are shown for various LPT polymer-abaparatide acetate formulations (AA1 = magnesium chloride, □; AA2 = calcium chloride, ■; AA3 = zinc chloride, ●) including divalent metal chlorides relative to control formulations without metal salts (AAX3 = no metal salt, ▲). The results show that the control formulation AAX8 (▲) degraded faster than formulations AA1, AA2, and AA3 and the peptide (abaparatide acetate) recovery was only 13% after 3 days at 37°C, and almost all of the peptide was lost after 7 days at 37°C. The LPT polymer-abaparatide acetate formulations including metal chloride salts all showed improved stabilization compared to formulations without metal salts, resulting in a higher percentage recovery of abaloparatide acetate over an extended period of time. The formulation including magnesium chloride (□) showed the highest level of stability, with approximately 82% abaparatide acetate recovered after 21 days at 37°C, followed by formulations including calcium chloride (■), and then formulations including zinc chloride (●).

[0186] These results demonstrate that the stability of abaparatide acetate in PEG-initiated LPT polymer formulations is further improved by including a divalent metal salt.

[0187] Embodiment 5: LPT formulations comprising abaparatide acetate and a magnesium salt

[0188] This example demonstrates that the stability of abaparatide is further improved by the addition of magnesium ions in LPT formulations including PEG-initiated LPT polymers.

[0189] Various LPT polymer-abaparatide formulations with and without metal salts were prepared according to the procedure outlined in Example 1. In this example, the copolymer used for all formulations was a PEG300 initiated PDLCL copolymer having a lactide to caprolactone molar ratio of about 75:25, and a lactide-caprolactone-ethylene glycol ratio of about 57:21.3:21.7, and an average molecular weight of 7.9 kDa (see, e.g., Table 1, Sample No. 9). The formulations included NMP as a solvent in an amount that resulted in a polymer to solvent weight ratio of about 40:60. To prepare LPT-peptide formulations including a magnesium salt, a mixture of abalaparatide acetate peptide and the corresponding magnesium salt was prepared (see Table 5) and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 5 mg abalaparatide acetate peptide relative to about 1000 mg LPT polymer solution (e.g., approximately 0.5% w / w peptide in the formulation).

[0190] The samples were incubated at 37°C until the target storage time was reached. The samples were analyzed for percent recovery of abaparatide acetate according to the procedure outlined in Example 2.

[0191] The results of the stability testing for formulations AA4-AA7 including metal salts, and control formulation AAX9 without metal salts are provided in Table 5 A. Table 5 A shows (1) the metal salts used, (2) the concentration of the metal salts in the final formulations, (3) the weight ratio of abaparatide acetate to metal salt in the final formulations (peptide:metal salt ratio), and (4) the recovery of abaparatide acetate from the LPT peptide-ababaparatide acetate formulations after storage at 37° C. for a given number of days.

[0192] Table 5A

[0193]

[0194] Figure 4 The results of stability testing at 37°C are shown for various PEG-initiated LPT polymer-abaparatide acetate formulations including magnesium salts, relative to control formulations without metal salts (AA4-AA7 and AAX9, respectively). The results show that the control formulation AAX9 (▲) degraded more than half of the abaloparatide acetate after 10 days of storage at 37°C, and only about 9% of the peptide was recovered from the 22-day storage sample. PEG-initiated LPT polymer-abaparatide including magnesium salts (both magnesium acetate (Mg(OAc)2) and magnesium chloride (MgCl2)) showed improved stabilization at all concentrations tested, resulting in less degradation of abaloparatide acetate during storage (see Figure 4 : AA6 = lower concentration MgCl2 (x); AA7 = higher concentration MgCl2 (□); AA4 = lower concentration Mg(OAc)2 (○); AA5 = higher concentration Mg(OAc)2 (◇)). For both MgCl2 and Mg(OAc)2, the higher concentration magnesium salts provide improved stabilization compared to the lower concentration magnesium salts.

[0195] To further evaluate the effect of magnesium acetate (Mg(OAc)2) on PEG-initiated LPT polymer-peptide formulations, a second experiment was conducted. In this experiment, a PEG300-initiated PDLCL copolymer having a lactide to caprolactone molar ratio of about 75:25 was prepared, resulting in a copolymer having a lactide to caprolactone to ethylene glycol molar ratio of 57:21.3:21.7 and an average molecular weight of 7.9 kDa (see Table 1 Sample No. 9). The formulation included NMP as a solvent in an amount to give a polymer to solvent weight ratio of about 40:60. To prepare an LPT-peptide formulation including magnesium acetate, a mixture of abaparatide acetate peptide and magnesium acetate was prepared and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 5 mg abaparatide acetate peptide relative to about 1000 mg LPT polymer solution (e.g., approximately 0.5% w / w peptide in the formulation).

[0196] The samples were incubated at 37°C until the target storage time was reached. The samples were analyzed for abaparatide acetate according to the procedure outlined in Example 2.

[0197] The results of the stability testing for formulations AA8 and AA9 including metal salts, and control formulation AAX10 without metal salts are provided in Table 5B. Table 5B shows (1) the metal salt used, (2) the concentration of the metal salt in the final formulation, (3) the weight ratio of peptide to metal salt in the final formulation; and (4) the percent recovery of abaloparatide acetate from the LPT peptide-ababaloparatide acetate formulation after storage at 37°C for a given number of days.

[0198] Table 5B

[0199]

[0200] Figure 5 Shown are the results of stability testing of test formulations AA8 (○) and AA9 (◇) relative to control formulation AAX10 (▲).

[0201] Figure 5 It was shown that the control formulation AAX10 (▲) degraded faster than formulations AA8 and AA9, and the recovery of abaloparatide acetate was only 30.82% after storage at 37°C for 3 days, and almost all of the peptide was degraded after storage at 37°C for 14 days. The PEG-initiated LPT polymer-ababaloparatide acetate formulations including magnesium acetate as the metal salt exhibited a slower peptide degradation curve relative to the control formulation. The addition of a lower concentration of magnesium acetate (0.55 mg / mL, AA8) (○) resulted in a higher recovery curve compared to the control formulation, and the difference was the largest at the shorter storage time of 3 days. The addition of a higher concentration of magnesium acetate (1.1 mg / mL, AA9) (◇) resulted in a significantly higher recovery curve throughout the 60-day storage period. In particular, after storage at 37°C for 60 days, about 78% of the peptide was recovered from the formulation. These results suggest that abaparatide acetate can be stabilized for prolonged storage by the addition of magnesium acetate, particularly when magnesium acetate is added at higher concentrations.

[0202] In conclusion, these results demonstrate that the stability of abaparatide acetate is improved in PEG-initiated LPT formulations by including an appropriate amount of magnesium salt.

[0203] Embodiment 6: LPT formulations comprising abaparatide acetate and zinc salt

[0204] This example demonstrates that the stability of abaparatide is further improved by the addition of zinc ions in LPT formulations including PEG-initiated LPT polymers.

[0205] Various LPT polymer-abaparatide acetate formulations with and without metal salts were prepared according to the procedure outlined in Example 1. In this experiment, a PEG300 initiated PDLCL copolymer having a lactide to caprolactone molar ratio of about 75:25 was prepared, resulting in a copolymer having a lactide to caprolactone to ethylene glycol molar ratio of 57:21.3:21.7 and an average molecular weight of 7.9 kDa (see Table 1 Sample No. 9). The formulation included NMP as a solvent in an amount to give a polymer to solvent weight ratio of about 40:60. To prepare LPT-peptide formulations including zinc salts (ZnCl2 or Zn(OAc)2), a mixture of abalaparatide acetate peptide and zinc salt was prepared and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 5 mg abalaparatide acetate peptide relative to about 1000 mg LPT polymer solution (e.g., approximately 0.5% w / w peptide in the formulation).

[0206] The samples were incubated at 37°C until the target storage time was reached. The samples were analyzed for abaparatide acetate according to the procedure outlined in Example 2.

[0207] Table 6 shows (1) the metal salt used in each of the test formulations, (2) the concentration of the metal salt in the final formulation, (3) the weight ratio of peptide to metal salt in the final formulation (peptide:metal salt ratio); and (4) the recovery of abaparatide acetate as a function of the number of days stored at 37°C for the test formulations AA10-AA12 and for the control formulation AAX11 that did not include a metal salt.

[0208] Table 6

[0209]

[0210]

[0211] Figure 6 Shown are the results of stability testing of test formulations AA10-AA12 relative to control formulation AAX11. Figure 6 It is shown that the PEG-initiated LPT polymer-abaparatide acetate formulation including zinc acetate as the metal salt also exhibited a higher recovery curve relative to the control formulation (▲). For the given period, a lower concentration of zinc acetate (2.5 mg / mL, AA10) was included The LPT polymer-abaparatide acetate formulation of resulted in higher recovery of abaloparatide compared to formulations including a higher concentration of zinc acetate (5.68 mg / mL, AA11) (+), with recovery of the peptide being approximately 40% versus 80% after storage at 37°C for 21 days. Figure 6It was also shown that LPT polymer-abaparatide acetate formulations including zinc chloride (1 mg / mL, AA12) (◆) showed higher recovery at 3 days of storage, but in this experiment, no enhanced stabilization of the peptide relative to the control formulation was shown at storage times of approximately 7 days and above.

[0212] These results suggest that the stability of abaparatide acetate in PEG-initiated LPT polymer formulations can be improved by including a zinc salt, and in particular zinc acetate.

[0213] Embodiment 7: LPT formulations comprising leuprolide acetate and LPT liquid polymers initiated with different polymer initiators

[0214] This example demonstrates that leuprolide acetate is more stable in LPT formulations including acid-initiated LPT polymers compared to PEG-initiated or dodecanol-initiated polymers.

[0215] Leuprolide acetate is a linear peptide that exemplifies a peptide having few, one, or no accessible amine groups. Specifically, leuprolide acetate is a linear nonapeptide containing one arginine group in its structure, i.e., it has one amine group, although as discussed below, according to the present invention, the amine group is not accessible due to steric hindrance caused by the bulky isobutyl group of D-leucine. Various LPT polymer-leuprolide acetate formulations were prepared according to the procedure outlined in Example 1. In this example, the LPT polymer in all cases was a copolymer of D,L-lactide and ε-caprolactone ("PDLCL") having a lactide to caprolactone molar ratio of about 75:25, wherein the copolymer was initiated with the indicated initiator (see Table 3,). In the case of the PEG300 initiated copolymer, the lactide to caprolactone to ethylene glycol ratio was about 49.3:18.2:32.6 (see Table 1 Sample No. 12). All formulations included NMP as solvent in an amount to give a copolymer to solvent weight ratio of about 40:60. In each formulation, about 4 mg of leuprolide acetate was combined with about 1000 mg of LPT polymer solution (eg, approximately 0.4% w / w peptide in the formulation).

[0216] The samples were incubated at 37°C until the target storage time was reached. The samples were analyzed for the amount of leuprolide acetate according to the procedure outlined in Example 2.

[0217] The results of the stability testing are provided in Table 7, which shows (1) the weight average molecular weight of the copolymer used in each of the formulations, (2) the initiator used to form the liquid copolymer, and (3) the recovery of leuprolide acetate from the LPT polymer-leuprolide acetate formulations after storage at 37°C for a given number of days.

[0218] Table 7

[0219] Formulation ID LAX1 LAX2 LAX3 Polymer MW (kDa) 5.3 kDa 6.6 kDa 4.3 kDa Initiator Glycolic acid PEG300 Dodecanol % Recovery at 0 Days 102.73 97.76 98.72 % Recovery at 3 days 85.30 26.14 25.66 % Recovery at 7 days 83.46 23.48 19.62 % Recovery at 14 days 62.49 20.48 18.15 % Recovery at 30 days 41.31 19.05 16.00

[0220] Figure 7 The recovery curves of LPT polymer-leuprolide acetate formulations (LAX1-LAX3) made with three initiators at 37°C are shown. The results show that the stability of leuprolide acetate in the acid-initiated polymer (■) is significantly higher than that prepared using the PEG-300-initiated polymer (▲) or the dodecanol-initiated polymer (●). For the acid-initiated polymer, the percentage recovery of leuprolide acetate after 30 days at 37°C was about 41%, while in the PEG-300-initiated and dodecanol-initiated polymers, the recoveries at 30 days were approximately 19% and 16%, respectively. The results show that the acid-initiated polymer provides an improved stability curve for the leuprolide acetate formulation compared to the dodecanol-initiated or PEG-initiated LPT polymers.

[0221] As discussed above, leuprolide acetate is a linear peptide containing one arginine group, i.e., one amine group, in its structure. Although arginine is more basic than lysine due to its resonance structure (which stabilizes / delocalizes the positive charge on arginine by donating electron pairs from the other two nitrogens on the side chain), leuprolide acetate is stable in acid-initiated LPT formulations, for example when compared to abaparatide acetate (which is unstable in acid-initiated LPT formulations). This unexpectedly higher stability of leuprolide acetate can be explained by the steric hindrance caused by the bulky isobutyl group of D-leucine, which protects the guanidinium group of arginine from the acidic environment and slows down the reaction with the polymer.

[0222] Embodiment 8: LPT formulations comprising leuprolide acetate and metal salts

[0223] This example demonstrates that the stability of leuprolide acetate is further improved by including divalent metal ions in LPT formulations including acid initiated polymers.

[0224] Various LPT polymer-leuprolide acetate formulations were prepared according to the procedure outlined in Example 1. In this example, the LPT polymer in all cases was a copolymer of D,L-lactide and ε-caprolactone ("PDLCL") having a lactide to caprolactone molar ratio of about 75:25, wherein the copolymer was initiated with glycolic acid to yield a copolymer having a weight average molecular weight of 5.3 kDa. All formulations included NMP as a solvent in an amount to give a copolymer to solvent weight ratio of about 40:60. To prepare LPT-peptide formulations including metal salts, mixtures of metal salts and leuprolide acetate peptide as shown in Table 8 were prepared and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 4 mg leuprolide acetate peptide relative to about 1000 mg LPT polymer solution (e.g., approximately 0.4% w / w peptide in the formulation).

[0225] The samples shown in Table 8 were incubated at 37°C until the target storage time was reached. The samples were analyzed for leuprolide acetate according to the procedure outlined in Example 2.

[0226] Table 8 shows (1) the metal salt used in each of the tested formulations, (2) the concentration of the salt in the final formulation, (3) the weight ratio of peptide to metal salt in the final formulation (peptide:metal salt ratio), and (4) the percent recovery (w / w) of leuprolide acetate after storage at 37°C for the indicated number of days.

[0227] Table 8

[0228]

[0229] Figure 8 The recovery curves of acid-induced leuprolide acetate formulations including a higher concentration of magnesium acetate (1.08 mg / mL, LA2) (◇) and a lower concentration of magnesium acetate (0.53 mg / mL, LA1) (○) are shown over a storage period of up to 60 days at 37°C, compared to a control formulation (LAX4) (■) that does not include a metal salt. The recovery curves of the three formulations are similar at 3 days and less storage time. At 7 days and longer storage time, the formulation including a higher concentration of magnesium acetate (1.08 mg / mL, LA2) shows improved stability compared to the control formulation and the formulation including a lower concentration of magnesium acetate (0.53 mg / mL, LA1), resulting in a higher recovery of leuprolide acetate. The recovery curves of the formulations including a lower concentration of magnesium acetate are similar to those of the control formulation. These results indicate that leuprolide acetate can be stabilized by a combination of acid-induced LPT polymers and magnesium acetate.

[0230] Fig. 9The inclusion of zinc acetate (2.14 mg / mL, LA3 and 5.0 mg / mL, LA4, respectively) (respectively) showed that the LA3 and LA4 formulations did not increase the activity of the metal salts over a storage period of up to 21 days at 37°C compared to an acid initiated control formulation (LAX4) (■) that did not include a metal salt. Recovery curves of acid-initiated LPT polymer-leuprolide acetate formulations with zinc chloride (0.15 mg / mL, LA5 and 0.93 mg / mL, LA6) ((●) and (◆) respectively) as metal salts. Leuprolide acetate in formulations including zinc chloride (LA5 and LA6) or zinc acetate (LA3 and LA4) degraded more slowly when compared to the control formulation, with formulations including zinc chloride or zinc acetate having significant differences in the recovery curves of leuprolide acetate at 7, 14 and 21 days compared to the control formulation. Formulations including higher concentrations of zinc chloride as the metal salt (0.93 mg / mL, LA6) (◆) showed the highest recovery, especially at longer storage times of 14 days and above.

[0231] These results indicate that the stability of leuprolide acetate in acid-initiated LPT polymer formulations can be improved by including zinc salts, including at lower and higher concentrations of such salts.

[0232] Example 9: LPT formulations comprising lanreotide acetate and LPT liquid polymer initiated with different polymer initiators and metal salts.

[0233] This example demonstrates that the stability of lanreotide acetate is improved in LPT formulations including acid-initiated LPT polymers, and that the stability of lanreotide acetate can be further improved by adding divalent metal ions such as magnesium or zinc.

[0234] LPT formulations including lanreotide acetate were made as described in Example 1 and are shown in Tables 9A and 9B. Lanreotide acetate is an exemplary cyclic peptide containing few, one or no accessible amine groups. Specifically, lanreotide acetate is a cyclic peptide containing one lysine group in its structure, i.e., according to the present invention, it has one accessible amine group. Various LPT polymer-lanreotide acetate formulations were prepared according to the procedure outlined in Example 1.

[0235] In this example, the LPT polymer in all cases was a copolymer of D,L-lactide and ε-caprolactone ("PDLCL") having a lactide to caprolactone molar ratio of about 75:25. In the experiments described in Table 9A, the copolymers were initiated with the indicated initiators to produce copolymers having the indicated weight average molecular weights. In the case of the PEG300 initiated copolymers in Table 9A, the lactide to caprolactone to ethylene glycol ratio was about 49.3:18.2:32.6 (see Table 1 Sample No. 12). In the experiments shown in Table 9B, the LPT polymer used in all test formulations was a 75:25 PDLCL initiated with glycolic acid having a weight average molecular weight of 5.3 kDa. All formulations included NMP as a solvent in an amount that resulted in a copolymer to solvent weight ratio of about 40:60. In each LPT formulation shown in Table 9A, about 3 mg of lanreotide acetate peptide was combined with about 1000 mg of LPT polymer solution (eg, approximately 0.3% w / w peptide in the formulation). Fig. 9 B, a mixture of the metal salt and lanreotide acetate peptide shown in Table 9B was prepared and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 3 mg lanreotide acetate peptide relative to about 1000 mg LPT polymer solution (e.g., approximately 0.3% w / w peptide in the formulation).

[0236] The samples were incubated at 37°C until the target storage time was reached. The samples were analyzed for the amount of lanreotide acetate according to the procedure outlined in Example 2.

[0237] Table 9A shows (1) the weight average molecular weight of the copolymer used in each of the formulations, (2) the initiator used to form the liquid copolymer, and (3) the recovery of lanreotide acetate after storage at 37° C. for 0, 3, and 7 days.

[0238] Table 9A

[0239] Formulation ID LNAX1 LNAX2 LNAX3 Polymer MW (kDa) 5.3 4.3 6.6 Initiator acid Dodecanol PEG300 % Recovery at 0 Days 104.83 93.74 86.77 % Recovery at 3 days 48.56 28.84 12.94 % Recovery at 7 days 28.70 6.43 0.00

[0240] Fig.10 The results of stability testing of the three formulations LNAX1 (acid initiated, (■)) LNAX2 (dodecanol initiated, (●)), and LNAX3 (PEG initiated, (▲)) are shown. Fig.10It was shown that in all three formulations LNAX1-LNAX3 that did not include a metal salt, the recovery of the peptide (lanreotide acetate) was significantly reduced after 3 days of storage at 37°C. In particular, in the formulations in which the polymer was initiated with dodecanol (LNAX2) (●) or PEG300 (LNAX3) (▲), essentially all of the polymer was lost after 7 days of storage at 37°C. The formulation including the acid-initiated copolymer (LNAX1) (■) showed greater stability, with approximately 30% of the lanreotide acetate recovered after 7 days of accelerated stability testing at 37°C. Thus, for the cyclic peptide having only one accessible amine group, the acid-initiated LPT polymer showed the greatest stability compared to the dodecanol-initiated or PEG-initiated polymers.

[0241] Table 9B shows the results of additional experiments in which metal salts were added to acid-initiated LPT formulations to determine whether the metal salts could improve the stability of the peptide. Table 9B shows: (1) the metal salt used in each of the test formulations, (2) the concentration of the salt in the final formulation, (3) the weight ratio of lanreotide acetate to metal salt in the final formulation (peptide: metal salt ratio), (4) and the recovery of lanreotide acetate after storage at 37°C for 0, 3, 7 and 14 days and in the case of zinc acetate and zinc chloride also after storage at 37°C for 21 days.

[0242] Table 9B

[0243]

[0244] Fig.11 Shown are the results of stability testing of test formulations LNA1 (●) and LNA2 (◆) which had two different concentrations of magnesium acetate added to the formulations relative to control formulation LNAX4 (■), which is a glycolic acid initiated 75:25 PDLCL with a weight average molecular weight of 5.3 kDa. Fig.11 It was shown that acid-triggered LPT polymer formulations, including lanreotide acetate drug formulations containing both lower (0.55 mg / mL, LNA1) (●) and higher (1.1 mg / mL, LNA2) (◆) concentrations of magnesium acetate, exhibited reduced or similar peptide stability at both 3 and 7 days relative to the acid-triggered control formulation (LNAX1) (■) that did not include a metal salt, and that essentially no peptide was recovered from the acid-triggered LPT formulation containing magnesium acetate after 14 days.

[0245] Fig.12 Compared with the control formulation LNAX4 (■), the test formulation LNA3 Results of accelerated stability testing of LNA4 (+), LNA5 (●) and LNA6 (◆) with added zinc acetate or zinc chloride at different concentrations. Fig.12 It was shown that the acid-initiated LPT polymer formulations including lanreotide acetate and zinc salt degraded more slowly at 37°C compared to the control formulation without metal salt. Fig.12 The percent recovery relative to the acid initiated control formulation (LNAX4) (■) showed a lower (2.3 mg / mL, LNA3) Stability curves of formulations with higher (5.0 mg / mL, LNA4) (+) concentrations of zinc acetate and lower (0.2 mg / mL, LNA5) (●) and higher (1.0 mg / mL, LNA6) (◆) concentrations of zinc chloride. Fig.12 As shown in Figure 5, all four tested formulations containing zinc salts exhibited improved stability over at least about 21 days of storage at 37°C, with particularly significant improvements at about 7 days. In particular, while formulations including zinc acetate and lower concentrations of zinc chloride all performed equally well, the formulation including a higher concentration of zinc chloride (LNA6, ◆) provided significantly improved peptide stability relative to the other tested formulations even across the entire length of the 21-day study.

[0246] These results indicate that the stability of lanreotide acetate in liquid polymer drug formulations can be improved by including a zinc salt. In particular, relatively high concentrations (about 1.0 mg / mL) of zinc chloride appear to allow recovery of at least about 40% of the peptide after storage for 21 days at 37°C. In particular, zinc acetate appears to provide the best stabilizing effect at lower concentrations, while zinc chloride appears to provide the best stabilizing effect at higher concentrations.

[0247] Example 10: LPT formulations comprising octreotide acetate and LPT liquid polymers initiated with different polymer initiators and metal salts

[0248] This example illustrates the stability of octreotide acetate in LPT formulations including LPT polymers synthesized using different initiators and divalent metal ions.

[0249] Octreotide acetate is another exemplary cyclic peptide containing few, one or no accessible amine groups. Specifically, octreotide acetate is a cyclic peptide containing one lysine group in its structure, i.e., according to the present invention, it has one accessible amine group. Various LPT polymer-octreotide acetate formulations were prepared according to the procedure outlined in Example 1. In this example, the LPT polymer in all cases was a copolymer of D,L-lactide and ε-caprolactone ("PDLCL") having a lactide to caprolactone molar ratio of about 75:25. In the experiments described in Table 10A, the copolymers were initiated with the indicated initiators to produce copolymers with the indicated weight average molecular weights. In the case of the PEG300-initiated copolymers in Table 10A, the lactide to caprolactone to ethylene glycol ratio was about 49.3:18.2:32.6 (see Table 1 Sample No. 12). In the experiments shown in Table 10B, the LPT polymer used in all test formulations was a glycolic acid initiated 75:25 PDLCL having a weight average molecular weight of 5.3 kDa. All formulations included NMP as a solvent in an amount to give a copolymer to solvent weight ratio of about 40:60. In each LPT formulation shown in Table 10A, about 3 mg of octreotide acetate peptide was combined with about 1000 mg of LPT polymer solution (e.g., approximately 0.3% peptide w / w of the formulation). To prepare Fig.10 B, a mixture of the metal salt and octreotide acetate peptide shown in Table 10B was prepared and lyophilized. The lyophilized peptide / metal salt mixture was then combined with an LPT polymer solution at about 3 mg of octreotide acetate peptide relative to about 1000 mg of LPT polymer solution (e.g., approximately 0.3% w / w peptide in the formulation).

[0250] The samples were incubated at 37°C until the target storage time was reached. The samples were analyzed for the amount of octreotide acetate according to the procedure outlined in Example 2.

[0251] Table 10A shows (1) the molecular weight of the copolymer used in each of the formulations, (2) the initiator used to form the liquid copolymer, and (3) the recovery of octreotide acetate as a function of storage time at 37°C.

[0252] Table 10A

[0253] Formulation ID OAX1 OAX3 OAX4 Polymer MW (kDa) 5.3 4.3 6.6 Initiator Glycolic acid Dodecanol PEG300 Recovery rate at 3 days (%) 24.74 20.52 7.99 Recovery rate at 7 days (%) 7.74 3.48 0.00

[0254] Fig.13 Shown are the results of stability testing of LPT polymer-octreotide acetate formulations, wherein the polymers were initiated with different polymer initiators as shown in Table 10A (OAX1 = acid (■), OAX3 = dodecanol initiated (●), and OAX4 = PEG300 initiated (▲)). Fig.13 It was shown that all three LPT polymer-octreotide acetate formulations (OAX1, OAX3 and OAX4) showed degradation of octreotide acetate after storage at 37°C, and the acid-initiated LPT polymer (■) showed slightly improved percent recovery compared to the dodecanol-initiated (●) or PEG-initiated (▲) polymers.

[0255] Table 10B shows the results of additional experiments in which magnesium acetate was added to the acid-initiated LPT formulation to determine whether the metal salt could improve the stability of the peptide. Table 10B shows: (1) the concentration of magnesium acetate in the final formulation, (2) the weight ratio of peptide to metal salt in the final formulation (peptide:metal salt ratio), and (3) the recovery of octreotide acetate after storage at 37°C for 0, 3, 7, and 14 days.

[0256] Table 10B

[0257] Formulation ID OAX2 OA1 OA2 Salt concentration (mg / mL) none 0.55 1.1 Peptide:metal salt ratio N / A 5.5∶1 2.7∶1 Recovery rate at 3 days (%) 25.42 19.77 13.19 Recovery rate at 7 days (%) 7.17 4.21 1.13 Recovery rate at 14 days (%) 0.82 1.02 0.19

[0258] Fig.14 Shown are the results of stability testing of acid initiated LPT polymer-octreotide acetate formulations OA1 (○) and OA2 (◇) including magnesium acetate relative to a control formulation not including magnesium acetate, OAX2 (●), which is a glycolic acid initiated 75:25 PDLCL with a weight average molecular weight of 5.3 kDa. Fig.14 It was shown that acid-initiated LPT polymer-octreotide acetate formulations including magnesium acetate as the metal salt were characterized by rapid degradation of the peptide at 37° C. Both formulations including magnesium acetate (lower concentration = OA1 (○) and higher concentration = OA2 (◇)) exhibited reduced peptide stability at both 3 and 7 days relative to the acid-initiated control formulation (OAX2) (■) that did not include a metal salt, and after 14 days, essentially no peptide was recovered from all three formulations, including the control formulation.

[0259] Considered together with the results shown in other embodiments, although it is expected that cyclic peptides such as lanreotide acetate and octreotide acetate are degraded more slowly than linear peptides such as leuprolide acetate, surprisingly, leuprolide acetate shows higher stability in acid-induced LPT formulations compared with lanreotide and octreotide. This may be mainly due to steric hindrance, which slows down the acylation (degradation) of leuprolide acetate. In addition, abaparatide acetate (which has a simple linear sequence like leuprolide acetate, but has a high number of accessible amine groups (i.e., active reaction sites) in addition) is likely to attract the acid-terminal groups of the PDLCL polymers triggered by acid, which results in high degradation in the presence of such acid-induced polymers. In contrast, for leuprolide acetate, lanreotide acetate and octreotide acetate with only one reaction site, hydrophilicity seems to play a dominant role in the degradation of peptides and therefore, these peptides are more rapidly degraded in the polymers triggered by PEG, wherein surprisingly, abaparatide acetate is especially more stable. Finally, for many of the LPT formulations, the addition of divalent metal salts improved stability, with magnesium salts and zinc acetate being particularly effective for use with PEG-initiated LPT polymers and peptides with a large number of accessible amine groups, and zinc salts being particularly effective for acid-initiated polymers and with few or no accessible amine groups.

[0260] Various modifications of the above-described invention will be apparent to those skilled in the art. It is intended that such modifications be included within the scope of the appended claims.

Claims

1. A pharmaceutical composition, comprising: a) an active pharmaceutical ingredient comprising a peptide or a pharmaceutically acceptable ester or salt thereof, wherein the peptide comprises at least one accessible amine group; b) A biodegradable copolymer comprising: i) a copolymer block comprising: (1) monomer residues selected from the group consisting of D,L-lactide, D-lactide, L-lactide, and glycolide, and combinations thereof, and (2) monomer residues selected from the group consisting of ϵ-caprolactone, trimethylene carbonate, and combinations thereof; and ii) a polymer block comprising low molecular weight polyethylene glycol (PEG); wherein the biodegradable copolymer is synthesized by initiating with the low molecular weight polyethylene glycol (PEG); and wherein the viscosity of the biodegradable copolymer does not spontaneously increase with increasing temperature; and c) divalent cations, wherein the composition further comprises a biocompatible solvent, wherein the divalent cation is selected from magnesium, calcium, and zinc, wherein the biodegradable copolymer is not a reverse thermogel, wherein the terminal groups of the biodegradable copolymer of (b) are not covalently modified, The low molecular weight polyethylene glycol is polyethylene glycol (PEG) having a number average molecular weight of no greater than 5,000 Daltons.

2. The pharmaceutical composition of claim 1, wherein the biodegradable copolymer is a triblock copolymer according to the formula: ABA, wherein A is the copolymer block of (i), and B is a polymer block comprising low molecular weight polyethylene glycol (PEG).

3. The pharmaceutical composition of claim 1, wherein the biodegradable copolymer is a diblock copolymer according to the formula: AB or BA, wherein A is the copolymer block of (i) and B is a polymer block comprising a low molecular weight polyethylene glycol (PEG), and wherein the low molecular weight polyethylene glycol (PEG) is methoxy-PEG.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the copolymer block of (i) has a molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomer residues between 10:90 and 90:

10.

5. The pharmaceutical composition of any one of claims 1 to 3, wherein the copolymer block of (i) has a molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomer residues between 20:80 and 80:

20.

6. The pharmaceutical composition of any one of claims 1 to 3, wherein the copolymer block of (i) has a molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomer residues of between 25:75 and 75:

25.

7. The pharmaceutical composition of any one of claims 1 to 3, wherein the copolymer block of (i) has a molar ratio of lactide monomer residues to caprolactone and / or trimethylene carbonate monomer residues of 75:

25.

8. The pharmaceutical composition of any one of claims 1 to 3, wherein the molar ratio of ethylene glycol residues in the polymer block comprising low molecular weight polyethylene glycol (PEG) to all other monomer residues in the biodegradable copolymer is between 10:90 and 50:

50.

9. The pharmaceutical composition of any one of claims 1-3, wherein the molar ratio of ethylene glycol residues in the polymer block comprising low molecular weight polyethylene glycol (PEG) to all other monomer residues in the biodegradable copolymer is at least 20:

80.

10. The pharmaceutical composition of any one of claims 1-3, wherein the molar ratio of ethylene glycol residues in the polymer block comprising low molecular weight polyethylene glycol (PEG) to all other monomer residues in the biodegradable copolymer is at least 30:

70.

11. The pharmaceutical composition of any one of claims 1-3, wherein the molar ratio of lactide or glycolide monomer residues to caprolactone and / or trimethylene carbonate monomers to ethylene glycol residues in the biodegradable copolymer is X:Y:Z, wherein X is any number between 25 and 75, Y is any number between 5 and 45, and Z is any number between 5 and 55, such that the sum of X, Y, and Z is 100.

12. The pharmaceutical composition of any one of claims 1 to 3, wherein the low molecular weight polyethylene glycol has a number average molecular weight of 200-2000 Daltons.

13. The pharmaceutical composition of any one of claims 1 to 3, wherein the number average molecular weight of the low molecular weight polyethylene glycol is less than or equal to 900 Daltons.

14. The pharmaceutical composition of any one of claims 1-3, wherein the number average molecular weight of the low molecular weight polyethylene glycol is less than or equal to 600 Daltons.

15. The pharmaceutical composition of any one of claims 1-3, wherein the number average molecular weight of the low molecular weight polyethylene glycol is less than or equal to 400 Daltons.

16. The pharmaceutical composition of any one of claims 1-3, wherein the number average molecular weight of the low molecular weight polyethylene glycol is less than or equal to 300 Daltons.

17. The pharmaceutical composition of any one of claims 1-3, wherein the divalent cation is provided as a metal salt.

18. The pharmaceutical composition of claim 17, wherein the metal salt is selected from the group consisting of magnesium acetate, magnesium chloride, calcium chloride, zinc chloride, and zinc acetate.

19. The pharmaceutical composition of claim 17, wherein the metal salt is magnesium acetate, and wherein the magnesium acetate is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 2.75 mg / mL of the pharmaceutical composition.

20. The pharmaceutical composition of claim 17, wherein the metal salt is magnesium chloride, and wherein the magnesium chloride is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 3.75 mg / mL of the pharmaceutical composition.

21. The pharmaceutical composition of claim 17, wherein the metal salt is calcium chloride, and wherein the calcium chloride is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 1.6 mg / mL of the pharmaceutical composition.

22. The pharmaceutical composition of claim 17, wherein the metal salt is zinc acetate, and wherein the zinc acetate is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 8.2 mg / mL of the pharmaceutical composition.

23. The pharmaceutical composition of claim 17, wherein the metal salt is zinc chloride, and wherein the zinc chloride is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 1.4 mg / mL of the pharmaceutical composition.

24. The pharmaceutical composition of any one of claims 1-3, wherein the peptide comprises at least two basic amino acids selected from the group consisting of arginine, histidine, lysine, and combinations thereof.

25. A pharmaceutical composition, comprising: a) an active pharmaceutical ingredient comprising a linear peptide or a pharmaceutically acceptable ester or salt thereof, wherein the linear peptide has no accessible amine groups; b) biocompatible solvent; c) a biodegradable copolymer comprising lactide residues and monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof, wherein the biodegradable copolymer comprises at least one carboxylic acid terminal group; and d) divalent cations, wherein the divalent cation is selected from magnesium and zinc, wherein the biodegradable copolymer is synthesized using a hydroxy acid initiator, The hydroxy acid initiator is glycolic acid.

26. The pharmaceutical composition of claim 25, wherein the divalent cation is provided as a metal salt.

27. The pharmaceutical composition of claim 26, wherein the metal salt is selected from the group consisting of magnesium acetate, zinc chloride, and zinc acetate.

28. The pharmaceutical composition of any one of claims 26-27, wherein the metal salt is magnesium acetate, wherein the magnesium acetate is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 1.65 mg / mL of the pharmaceutical composition.

29. The pharmaceutical composition of any one of claims 26-27, wherein the metal salt is zinc chloride, and wherein the zinc chloride is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 1.1 mg / mL of the pharmaceutical composition.

30. The pharmaceutical composition of any one of claims 26-27, wherein the metal salt is zinc acetate, wherein the zinc acetate is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 7.15 mg / mL of the pharmaceutical composition.

31. A pharmaceutical composition, comprising: a) an active pharmaceutical ingredient comprising a cyclic peptide or a pharmaceutically acceptable ester or salt thereof, wherein the cyclic peptide has no accessible amine group or has one accessible amine group; b) biocompatible solvent; c) a biodegradable copolymer comprising lactide residues and monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof, wherein the biodegradable copolymer comprises at least one carboxylic acid terminal group; and d) divalent cations, wherein the divalent cation is zinc, wherein the biodegradable copolymer is formed using a hydroxy acid initiator, The hydroxy acid initiator is glycolic acid.

32. The pharmaceutical composition of claim 31, wherein the divalent cation is provided as a metal salt.

33. The pharmaceutical composition of claim 32, wherein the metal salt is selected from zinc chloride and zinc acetate.

34. The pharmaceutical composition of any one of claims 32-33, wherein the metal salt is zinc chloride, wherein the zinc chloride is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 1.4 mg / mL of the pharmaceutical composition.

35. The pharmaceutical composition of any one of claims 32-33, wherein the metal salt is zinc acetate, wherein the zinc acetate is at a concentration between 0.01 mg / mL of the pharmaceutical composition and 7.3 mg / mL of the pharmaceutical composition.

36. The pharmaceutical composition of any one of claims 1-3, 25-27 and 31-33, wherein the weight average molecular weight of the biodegradable copolymer is between 1 kDa and 35 kDa.

37. The pharmaceutical composition of any one of claims 1-3, 25-27 and 31-33, wherein the biocompatible solvent is selected from the group consisting of N-methyl-2-pyrrolidone (NMP), acetone, butyrolactone, ε-caprolactone, N-cyclohexyl-2-pyrrolidone, diethylene glycol monomethyl ether, dimethylacetamide, dimethylformamide, dimethyl sulfoxide (DMSO), ethyl acetate, ethyl lactate, N-ethyl-2-pyrrolidone, glycerol formal, ethoxylated tetrahydrofurfuryl alcohol, N-hydroxyethyl-2-pyrrolidone, isopropyl glycerol, lactic acid, methoxy polyethylene glycol, methoxypropylene glycol, methyl acetate, methyl ethyl ketone, methyl lactate, low molecular weight (MW) polyethylene glycol (PEG), polysorbate 80, polysorbate 60, polysorbate 40, polysorbate 20, polyoxyl 35 hydrogenated castor oil, polyoxyl 40 hydrogenated castor oil, sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, benzyl alcohol, n-propanol, isopropanol, t-butyl alcohol, propylene glycol, 2-pyrrolidone, alpha-tocopherol, triacetin, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, triethyl citrate, furfural, and esters thereof, and combinations and mixtures thereof.

38. The pharmaceutical composition of any one of claims 1-3, 25-27, and 31-33, wherein the biocompatible solvent comprises N-methyl-2-pyrrolidone (NMP).

39. The pharmaceutical composition of any one of claims 1-3, 25-27 and 31-33, wherein the composition has a viscosity suitable for injection at room temperature.

40. The pharmaceutical composition of any one of claims 1-3, 25-27 and 31-33, wherein After administration of the pharmaceutical composition to an animal, the biocompatible solvent dissipates in the animal's body and the biodegradable copolymer forms a biodegradable, non-solid implant in situ in the animal's body.

41. A delivery system for administration of a pharmaceutical composition, comprising: a) Syringes; and b) a pharmaceutical composition according to any one of claims 1 to 40, wherein said composition is contained within said syringe.

42. The delivery system of claim 41, wherein the syringe is a mixing syringe.

43. The delivery system of claim 41, wherein the injector is an autoinjector.